


31.08.05



**WORLD INTELLECTUAL PROPERTY ORGANIZATION
ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE**

34, chemin des Colombettes, Case postale 18, CH-1211 Genève 20 (Suisse)
Téléphone: (41 22) 338 91 11 - e-mail: wipo.mail @ wipo.int. - Fac-similé: (41 22) 733 54 28

PCT/IB04/04463

**PATENT COOPERATION TREATY (PCT)
TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)**

**CERTIFIED COPY OF THE INTERNATIONAL APPLICATION AS FILED
AND OF ANY CORRECTIONS THERETO**

**COPIE CERTIFIÉE CONFORME DE LA DEMANDE INTERNATIONALE, TELLE QU'ELLE
A ÉTÉ DÉPOSÉE, AINSI QUE DE TOUTES CORRECTIONS Y RELATIVES**

International Application No. } PCT/IB 0 3 / 0 6 4 6 4
Demande internationale n° }

International Filing Date } 18 DECEMBER 2003
Date du dépôt international } (18. 12. 03)

Geneva/Genève, 26 SEPTEMBER 2005
(26.09.05)

**International Bureau of the
World Intellectual Property Organization (WIPO)**

**Bureau International de l'Organisation Mondiale
de la Propriété Intellectuelle (OMPI)**

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



G. Beijer

Head, PCT Receiving and Processing Section
Chef de la section de la réception et du traitement du PCT

BEST AVAILABLE COPY

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.	PCT / IB 03 / 06464
International Filing Date	18 DECEMBER 2003 (18. 12. 03)
INTERNATIONAL BUREAU OF WIPO Name of receiving Office and "International Application"	
Applicant's or agent's file reference (if desired) (12 characters maximum)	BGI-159PC

Box No. I TITLE OF INVENTION

METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

Box No. II APPLICANT

☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BASF AKTIENGESELLSCHAFT
ZDZ/G
D-67056 Ludwigshafen
Germany

Telephone No.

Facsimile No.

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

UNIVERSITY OF SAARBRÜCKEN

This person is:

☒ applicant only

☐ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (i.e. country) of nationality:

State (i.e. country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

HANLEY, Elizabeth A.
Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109
United States of America

Telephone No.

(617) 227-7400

Facsimile No.

(617) 742-4214

Teleprinter No.

Agent's registration No. with the Office
33, 505

☒ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
<i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> ZELDER, Oskar Rossmarktstr. 27 67346 Speyer Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality: DE	State <i>(that is, country)</i> of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> KLOPPROGGE, Corinna Diemersteinstrasse 3 67056 Ludwigshafen Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality: DE	State <i>(that is, country)</i> of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> SCHRÖDER, Hartwig Goethestr. 5 69226 Nussloch Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality: DE	State <i>(that is, country)</i> of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> HAEFNER, Stefan Luipoldstrasse 11 67063 Ludwigshafen Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality: DE	State <i>(that is, country)</i> of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.	

Sheet No. 3 of 7

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
<i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)</p> <p>KRÖGER, Burkhard Im Waldhof 1 67117 Limburgerhof Germany</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p> <p>Applicant's registration No. with the Office</p>
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>KIEFER, Patrick</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p> <p>Applicant's registration No. with the Office</p>
State (that is, country) of nationality: DE	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>HEINZLE, Elmar</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p> <p>Applicant's registration No. with the Office</p>
State (that is, country) of nationality: DE	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</p> <p>WITTMANN, Christoph</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p> <p>Applicant's registration No. with the Office</p>
State (that is, country) of nationality: DE	State (that is, country) of residence:
<p>This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box</p>	
<p><input type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.</p>	

Box No. IX CHECK LIST; LANGUAGE OF FILING

This international application contains:	This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):	Number of items
(a) in paper form, the following number of sheets:	1. <input checked="" type="checkbox"/> fee calculation sheet	1
request (including declaration sheets) : 7	2. <input type="checkbox"/> original separate signed power of attorney	:
description (excluding sequence listings and/or tables related thereto) : 58	3. <input type="checkbox"/> original general power of attorney	:
claims : 3	4. <input type="checkbox"/> copy of general power of attorney; reference number, if any:	:
abstract : 1	5. <input type="checkbox"/> statement explaining lack of signature	:
drawings : 5	6. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):	:
Sub-total number of sheets : 74	7. <input type="checkbox"/> translation of international application into (language):	:
sequence listings : 16	8. <input type="checkbox"/> separate indications concerning deposited microorganisms or other biological material	:
tables related thereto :	9. <input checked="" type="checkbox"/> sequence listing in computer readable form (indicate type and number of carriers)	:
(for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below)	(i.) <input checked="" type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)	diskette (1)
Total number of sheets : 90	(ii) <input type="checkbox"/> (only where check-box (b)(i) or (c)(i) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter	:
(b) <input type="checkbox"/> only in computer readable form (Section 801(a)(i))	(iii) <input checked="" type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listings part mentioned in left column	1
(i) <input type="checkbox"/> sequence listings	10. <input type="checkbox"/> tables in computer readable form related to sequence listings (indicate type and number of carriers)	:
(ii) <input type="checkbox"/> tables related thereto	(i) <input type="checkbox"/> copy submitted for the purposes of international search under Section 802 (b-quarter) only (and not as part of the international application)	:
(c) <input type="checkbox"/> also in computer readable form (Section 801(a)(ii))	(ii) <input type="checkbox"/> (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including where applicable, the copy for the purposes of international search under Section 802 (b-quarter)	:
(i) <input type="checkbox"/> sequence listings	(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column	:
(ii) <input type="checkbox"/> tables related thereto	11. <input checked="" type="checkbox"/> other Transmittal letter; certificate of express mailing and return postcard	3
Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the	(specify):	:
<input type="checkbox"/> sequence listings:		
<input type="checkbox"/> tables related thereto:		
(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)		

Figure of the drawings which should accompany the abstract: None

Language of filing of the international application: English

Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

Lisa M. DiRocco 18 December 2003
 Lisa M. DiRocco, Agent for BASF Aktiengesellschaft, et al.

For receiving Office use only

1. Date of actual receipt of the purported international application:	DT20 Rec'd PCT/PTO 18 DEC 2003	2. Drawings:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		<input type="checkbox"/> received:
4. Date of timely receipt of the required corrections under PCT Article 11(2):		<input type="checkbox"/> not received:
5. International Searching Authority (if two or more are competent):	ISA /	6. <input checked="" type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only	
PCT/IB 03 006464	
International Application No.	
18 DECEMBER 2003 (18.12.03)	
International Filing Date	
INTERNATIONAL BUREAU OF WIPO	
Name of receiving Office and PCT International Application No.	
Applicant's or agent's file reference (if desired) (12 characters maximum)	BGI-159PC

Box No. I TITLE OF INVENTION

METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

Box No. II APPLICANT

☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BASF AKTIENGESELLSCHAFT
GVX/G
D-67056 Ludwigshafen
Germany

Telephone No.

Facsimile No.

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

UNIVERSITY OF SAARBRÜCKEN
Postfach 15 11 50
66041 Saarbrücken
Germany

This person is:

☒ applicant only

☐ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (i.e. country) of nationality:

DE

State (i.e. country) of residence:

DE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☐ agent

☒ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

c/o HANLEY, Elizabeth A. BASF AKTIENGESELLSCHAFT
Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109
United States of America

Telephone No.

(617) 227-7400

Facsimile No.

(617) 742-4214

Teleprinter No.

Agent's registration No. with the Office
33,505

☒ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ZELDER, Oskar
Rossmarktstr. 27
67346 Speyer
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KLOPPRÖGGE, Corinna
Diemersteinstrasse 3
67056 Ludwigshafen
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SCHRÖDER, Hartwig
Goethestr. 5
69226 Nussloch
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HAEFNER, Stefan
Luipoldstrasse 11
67063 Ludwigshafen
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)

KRÖGER, Burkhard
Im Waldhof 1
67117 Limburgerhof
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KIEFER, Patrick
Am Homburg 59
66123 Saarbrücken
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE^a

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HEINZLE, Elmar
Senator - Richard - Becker - Straße 48
66123 Saarbrücken
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE^a

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WITTMANN, Christoph
Am Kalkofen 13
66127 Saarbrücken
Germany

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE^a

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

PCT/IB 03 / 0 6 4 6 4

International Application No.

18 DECEMBER 2003

International Filing Date

(23.07.04)
13
(18.12.03)

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum)

BGI-159PC

Box No. I TITLE OF INVENTION

METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

Box No. II APPLICANT

☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BASF AKTIENGESSELLSCHAFT
ZDZ/G
D-67056 Ludwigshafen
Germany

Telephone No.

Facsimile No.

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

UNIVERSITY OF SAARBRÜCKEN
Postfach 151150
66041 Saarbrücken
Germany

This person is:

☒ applicant only

☐ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (i.e. country) of nationality:
DE

State (i.e. country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☐ agent

☒ ^A common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)^A

HANLEY, Elizabeth A. / BASF AKTIENGESSELLSCHAFT^A
Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109
United States of America

Telephone No.

(617) 227-7400

Facsimile No.

(617) 742-4214

Teleprinter No.

Agent's registration No. with the Office
33,505

☒ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)	
<i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> ZELDER, Oskar Rossmarktstr. 27 67346 Speyer Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> <hr/> Applicant's registration No. with the Office
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> KLOPPROGGE, Corinna Diemersteinstrasse 3 67056 Ludwigshafen Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> <hr/> Applicant's registration No. with the Office
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> SCHRÖDER, Hartwig Goethestr. 5 69226 Nussloch Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> <hr/> Applicant's registration No. with the Office
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> HAEFNER, Stefan Luipoldstrasse 11 67063 Ludwigshafen Germany	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> <hr/> Applicant's registration No. with the Office
State (that is, country) of nationality: DE	State (that is, country) of residence: DE
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.	

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)*If none of the following sub-boxes is used, this sheet should not be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (i.e. country) of residence if no State of residence is indicated below.)

KRÖGER, Burkhard
Im Waldhof 1
67117 Limburgerhof
Germany

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DEState (that is, country) of residence:
DEThis person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KIEFER, Patrick
AM Homburg 5G
66123 Saarbrücken
Germany

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DEState (that is, country) of residence:
DEThis person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HEINZLE, Elmar
Senator-Richard-Becher-Straße 48
66123 Saarbücken
Germany

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DEState (that is, country) of residence:
DEThis person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WITTMANN, Christoph
Am Kalkofen 13
66127 Saarbücken
Germany

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
DEState (that is, country) of residence:
DEThis person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Sheet No. 4 of 7

Box No. V DESIGNATION OF STATES *Mark the applicable check-boxes; at least one must be marked.*

The following designations are hereby made under Rule 4.9(a):

Regional Patent

- ☒ **AP** **ARIPO Patent:** BW Botswana, GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** **Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** **European Patent:** AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, HU Hungary, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, RO Romania, SE Sweden, SI Slovenia, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** **OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT

National Patent *(if other kind of protection or treatment desired, specify on dotted line):*

- | | | |
|--|---|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> OM Oman |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> PG Papua New Guinea |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> PH Philippines |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> SC Seychelles |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> KR Republic of Korea | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> SY Syrian Arab Republic |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LR Liberia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> LS Lesotho | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> CO Columbia | <input checked="" type="checkbox"/> LT Lithuania | <input checked="" type="checkbox"/> TN Tunisia |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> LU Luxembourg | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> LV Latvia | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> MA Morocco | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> MD Republic of Moldova | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> MG Madagascar | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> MN Mongolia | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> EC Ecuador | <input checked="" type="checkbox"/> MW Malawi | <input checked="" type="checkbox"/> VC Saint Vincent and the Grenadines |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> MX Mexico | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> MZ Mozambique | <input checked="" type="checkbox"/> YU Serbia and Montenegro |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> NI Nicaragua | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> NO Norway | <input checked="" type="checkbox"/> ZM Zambia |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> NZ New Zealand | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> BW Botswana | <input type="checkbox"/> |
| <input checked="" type="checkbox"/> GH Ghana | | |
| <input checked="" type="checkbox"/> GM Gambia | | |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

☒ **EG** Egypt

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Supplemental Box *If the Supplemental Box is not used, this sheet should not be included in the request.*

1. *If, in any of the Boxes except Boxes Nos. VIII(i) to (v) for which a special continuation box is provided, the space is insufficient to furnish all the information: in such case, write "Continuation of box No. ..." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:*
 - (i) *if more than two persons are to be indicated as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;*
 - (ii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;*
 - (iii) *if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;*
 - (iv) *if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box IV;*
 - (v) *if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;*
 - (vi) *if, in Box No. VI, there are more than five earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;*
2. *If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.*

Continuation of Box No. IV:

James E. Cockfield, 19,162; Thomas V. Smurzynski, 24,798; Ralph A. Loren, 29,325; Giulio A. DeConti, Jr., 31,503; Elizabeth A. Hanley, 33,505; Amy E. Mandragouras, 36,207; Anthony A. Laurentano, 38,220; Kevin J. Canning, 35,470; Jane E. Remillard, 38,872; DeAnn F. Smith, 36,683; Jeanne M. DiGiorgio, 41,710; Megan E. Williams, 43,270; Jeremiah Lynch, 17,425; David J. Rikkers, 43,882; * Maria Laccotripe Zacharakis, Ph.D.; Debra J. Milasincic, 46,931; David R. Burns, 46,590; Sean D. Detweiler, 42,482; Cynthia L. Kanik, Ph.D., 37,320; Theodore R. West, 47,202; Hathaway P. Russell, 46,488; John S. Curran, 50,445; Lisa M. DiRocco, 51,619; Danielle L. Herritt, 43,670; Cynthia M. Soroos, 53,623; Jonathan M. Sparks, Ph.D., 53,624; Merideth C. Arnold, 52,568; Peter W. Dini, Ph.D., 52,821; Andriana Williams Zink, 54,539; and John D. Lanza, 40,060
 * Limited Recognition Under 37 C.F.R. § 10.9(b)

Sheet No. 6 of 7

Box No. VI PRIORITY CLAIM

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application:* regional Office	international application receiving Office
item (1)				
item (2)				
item (3)				
item (4)				
item (5)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☐ all items ☐ item (1) ☐ item (2) ☐ item (3) ☐ item (4) ☐ item (5) ☐ other, see Supplemental Box

* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)).

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code maybe used):

ISA /EP

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year) Number Country (or regional Office)

Box No. VIII DECLARATIONS

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

Number of
declarations


- | | | |
|---|--|---|
| <input type="checkbox"/> Box No. VIII (i) | Declaration as to the identity of the inventor | : |
| <input type="checkbox"/> Box No. VIII (ii) | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent | : |
| <input type="checkbox"/> Box No. VIII (iii) | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application | : |
| <input type="checkbox"/> Box No. VIII (iv) | Declaration of inventorship (only for the purposes of the designation of the United States of America) | : |
| <input type="checkbox"/> Box No. VIII (v) | Declaration as to non-prejudicial disclosures or exceptions to lack of novelty | : |

Box No. IX CHECK LIST; LANGUAGE OF FILING

This international application contains:		This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):		Number of items
(a) in paper form, the following number of sheets:		1. <input checked="" type="checkbox"/> fee calculation sheet	:	1
request (including declaration sheets)	: 7	2. <input type="checkbox"/> original separate signed power of attorney	:	
description (excluding sequence listings and/or tables related thereto)	: 58	3. <input type="checkbox"/> original general power of attorney	:	
claims	: 3	4. <input type="checkbox"/> copy of general power of attorney; reference number, if any:	:	
abstract	: 1	5. <input type="checkbox"/> statement explaining lack of signature	:	
drawings	: 5	6. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):	:	
Sub-total number of sheets	: 74	7. <input type="checkbox"/> translation of international application into (language):	:	
sequence listings	: 16	8. <input type="checkbox"/> separate indications concerning deposited microorganisms or other biological material	:	
tables related thereto	:	9. <input checked="" type="checkbox"/> sequence listing in computer readable form (indicate type and number of carriers)	:	
(for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below)		(i.) <input checked="" type="checkbox"/> copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)	:	diskette (1)
Total number of sheets	: 90	(ii.) <input type="checkbox"/> (only where check-box (b)(i) or (c)(i) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter	:	
(b) <input type="checkbox"/> only in computer readable form (Section 801(a)(i))		(iii.) <input checked="" type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the sequence listings part mentioned in left column	:	1
(i) <input type="checkbox"/> sequence listings		10. <input type="checkbox"/> tables in computer readable form related to sequence listings (indicate type and number of carriers)	:	
(ii) <input type="checkbox"/> tables related thereto		(i) <input type="checkbox"/> copy submitted for the purposes of international search under Section 802 (b-quarter) only (and not as part of the international application)	:	
(c) <input type="checkbox"/> also in computer readable form (Section 801(a)(ii))		(ii) <input type="checkbox"/> (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including where applicable, the copy for the purposes of international search under Section 802 (b-quarter)	:	
(i) <input type="checkbox"/> sequence listings		(iii) <input type="checkbox"/> together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column	:	
(ii) <input type="checkbox"/> tables related thereto		11. <input checked="" type="checkbox"/> other Transmittal letter; certificate of express mailing and return postcard	:	3
Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the		(specify):		
<input type="checkbox"/> sequence listings:				
<input type="checkbox"/> tables related thereto:				
(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)				
Figure of the drawings which should accompany the abstract: None		Language of filing of the international application: English		

Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

i.A.  April 2004

BASF Aktiengesellschaft i.A. O. Mechnich

For receiving Office use only		2. Drawings:	
1. Date of actual receipt of the purported international application:		<input type="checkbox"/> received:	
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		<input type="checkbox"/> not received:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):			
5. International Searching Authority (if two or more are competent) ISA /		6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only	
Date of receipt of the record copy by the International Bureau:	

METHODS FOR THE PREPARATION OF A FINE CHEMICAL BY FERMENTATION

Background of the Invention

5 The industrial production of the amino acid lysine has become an economically important industrial process. lysine is used commercially as an animal feed supplement, because of its ability to improve the quality of feed by increasing the absorption of other amino acids, in human medicine, particularly as ingredients of infusion solutions, and in the pharmaceutical industry.

10 Commercial production of this lysine is principally done utilizing the gram positive *Corynebacterium glutamicum*, *Brevibacterium flavum* and *Brevibacterium lactofermentum* (Kleemann, A., et. al., "Amino Acids," in ULLMANN'S
ENCYCLOPEDIA OF INDUSTRIAL CHEMISTRY, vol. A2, pp.57-97, Weinham:
VCH-Verlagsgesellschaft (1985)). These organisms presently account for the
15 approximately 250,000 tons of lysine produced annually. A significant amount of research has gone into isolating mutant bacterial strains which produce larger amounts of lysine. Microorganisms employed in microbial process for amino acid production are divided into 4 classes: wild-type strain, auxotrophic mutant, regulatory mutant and
20 auxotrophic regulatory mutant (K. Nakayama *et al.*, in *Nutritional Improvement of Food and Feed Proteins*, M. Friedman, ed., (1978), pp. 649-661). Mutants of
Corynebacterium and related organisms enable inexpensive production of amino acids from cheap carbon sources, *e.g.*, molasses, acetic acid and ethanol, by direct fermentation. In addition, the stereospecificity of the amino acids produced by
25 fermentation (the L isomer) makes the process advantageous compared with synthetic processes.

 Another method in improving the efficiency of the commercial production of lysine is by investigating the correlation between lysine production and metabolic flux through the pentose phosphate pathway. Given the economic importance of lysine production by the fermentive process, the biochemical pathway for lysine
30 synthesis has been intensively investigated, ostensibly for the purpose of increasing the total amount of lysine produced and decreasing production costs (reviewed by Sahm *et al.*, (1996) *Ann. N. Y. Acad. Sci.* 782:25-39). There has been some success in using metabolic engineering to direct the flux of glucose derived carbons toward aromatic amino acid formation (Flores, N. *et al.*, (1996) *Nature Biotechnol.* 14:620-623). Upon
35 cellular absorption, glucose is phosphorylated with consumption of phosphoenolpyruvate (phosphotransferase system) (Malin & Bourd, (1991) *Journal of Applied Bacteriology* 71, 517-523) and is then available to the cell as glucose-6-phosphate. Sucrose is converted into fructose and glucose-6-phosphate by a

phosphotransferase system (Shio *et al.*, (1990) *Agricultural and Biological Chemistry* 54, 1513-1519) and invertase reaction (Yamamoto *et al.*, (1986) *Journal of Fermentation Technology* 64, 285-291).

During glucose catabolism, the enzymes glucose-6-phosphate dehydrogenase (EC 1.1.14.9) and glucose-6-phosphate isomerase (EC 5.3.1.9) compete for the substrate glucose-6-phosphate. The enzyme glucose-6-phosphate isomerase catalyses the first reaction step of the Embden-Meyerhof-Parnas pathway, or glycolysis, namely conversion into fructose-6-phosphate. The enzyme glucose-6-phosphate dehydrogenase catalyses the first reaction step of the oxidative portion of the pentose phosphate cycle, namely conversion into 6-phosphogluconolactone.

In the oxidative portion of the pentose phosphate cycle, glucose-6-phosphate is converted into ribulose-5-phosphate, so producing reduction equivalents in the form of NADPH. As the pentose phosphate cycle proceeds further, pentose phosphates, hexose phosphates and triose phosphates are interconverted. Pentose phosphates, such as for example 5-phosphoribosyl-1-pyrophosphate are required, for example, in nucleotide biosynthesis. 5-Phosphoribosyl-1-pyrophosphate is moreover a precursor for aromatic amino acids and the amino acid L-histidine. NADPH acts as a reduction equivalent in numerous anabolic biosyntheses. Four molecules of NADPH are thus consumed for the biosynthesis of one molecule of lysine from oxalacetic acid. Thus, carbon flux towards oxaloacetate (OAA) remains constant regardless of system perturbations (J. Vallino *et al.*, (1993) *Biotechnol. Bioeng.*, 41, 633-646).

Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes, *e.g.*, glycerol kinase, of the pentose phosphate pathway in *Corynebacterium glutamicum*, and the discovery that deregulation, *e.g.*, decreasing expression or activity of glycerol kinase results in increased lysine production. Furthermore, it has been found that increasing the carbon yield during production of lysine by deregulating, *e.g.*, decreasing, glycerol kinase expression or activity leads to increased lysine production. In one embodiment, the carbon source is fructose or sucrose. Accordingly, the present invention provides methods for increasing production of lysine by microorganisms, *e.g.*, *C. glutamicum*, where fructose or sucrose is the substrate.

Accordingly, in one aspect, the invention provides methods for increasing metabolic flux through the pentose phosphate pathway in a microorganism comprising culturing a microorganism comprising a gene which is deregulated under conditions such that metabolic flux through the pentose phosphate pathway is increased. In one embodiment, the microorganism is fermented to produce a fine chemical, *e.g.*, lysine. In

another embodiment, fructose or sucrose is used as a carbon source. In still another embodiment, the gene is glycerol kinase. In a related embodiment, the glycerol kinase gene is derived from *Corynebacterium*, e.g., *Corynebacterium glutamicum*. In another embodiment, glycerol kinase gene is underexpressed. In a further embodiment, the protein encoded by the glycerol kinase gene has decreased activity. In another embodiment, the microorganism further comprises one or more additional deregulated genes.

In one embodiment, the microorganisms used in the methods of the invention belong to the genus *Corynebacterium*, e.g., *Corynebacterium glutamicum*.

In another aspect, the invention provides methods for producing a fine chemical comprising fermenting a microorganism in which glycerol kinase is deregulated and accumulating the fine chemical, e.g., lysine, in the medium or in the cells of the microorganisms, thereby producing a fine chemical. In one embodiment, the methods include recovering the fine chemical. In another embodiment, the glycerol kinase gene is underexpressed. In yet another embodiment, fructose or sucrose is used as a carbon source.

In one aspect, glycerol kinase is derived from *Corynebacterium glutamicum* and comprises the nucleotide sequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:2.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1: is a schematic representation of the pentose biosynthetic pathway.

Figure 2: Comparison of relative mass isotopomer fractions of secreted lysine and trehalose measured by GC/MS in tracer experiments of *Corynebacterium glutamicum* ATCC 21526 during lysine production on glucose and fructose.

Figure 3: *In vivo* carbon flux distribution in the central metabolism of *Corynebacterium glutamicum* ATCC 21526 during lysine production on glucose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopomer modeling for ^{13}C tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively. Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux

reversibilities. All fluxes are expressed as a molar percentage of the mean specific glucose uptake rate ($1.77 \text{ mmol g}^{-1} \text{ h}^{-1}$).

5 **Figure 4:** *In vivo* carbon flux distribution in the central metabolism of *Corynebacterium glutamicum* ATCC 21526 during lysine production on fructose estimated from the best fit to the experimental results using a comprehensive approach of combined metabolite balancing and isotopomer modeling for ^{13}C tracer experiments with labeling measurement of secreted lysine and trehalose by GC/MS, respectively. Net fluxes are given in square symbols, whereby for reversible reactions the direction of the net flux is indicated by an arrow aside the corresponding black box. Numbers in brackets below the
10 fluxes of transaldolase, transketolase and glucose 6-phosphate isomerase indicate flux reversibilities. All fluxes are expressed as a molar percentage of the mean specific fructose uptake rate ($1.93 \text{ mmol g}^{-1} \text{ h}^{-1}$).

15 **Figure 5:** Metabolic network of the central metabolism for glucose-grown (A) and fructose-grown (B) lysine producing *Corynebacterium glutamicum* including transport fluxes, anabolic fluxes and fluxes between intermediary metabolite pools.

Detailed Description of the Invention

20 The present invention is based at least in part, on the identification of genes, *e.g.*, *Corynebacterium glutamicum* genes, which encode essential enzymes of the pentose phosphate pathway. The present invention features methods comprising manipulating the pentose phosphate biosynthetic pathway in a microorganism, *e.g.*, *Corynebacterium glutamicum* such that the carbon yield is increased and certain
25 desirable fine chemicals, *e.g.*, lysine, are produced, *e.g.*, produced at increased yields. In particular, the invention includes methods for producing fine chemicals, *e.g.*, lysine, by fermentation of a microorganism, *e.g.*, *Corynebacterium glutamicum*, having deregulated, *e.g.*, decreased, glycerol kinase expression or activity. In one embodiment, fructose or saccharose is used as a carbon source in the fermentation of the
30 microorganism. Fructose has been established to be a less efficient substrate for the production of fine chemicals, *e.g.*, lysine, from microorganisms. However, the present invention provides methods for optimizing production of lysine by microorganisms, *e.g.*, *C. glutamicum* where fructose or sucrose is the substrate. Deregulation, *e.g.*, reduction, of glycerol kinase expression or activity leads to a higher flux through the pentose
35 phosphate pathway, resulting in increased NADPH generation and increased lysine yield.

The term "pentose phosphate pathway" includes the pathway involving pentose phosphate enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, *e.g.*, lysine. The pentose phosphate pathway converts glucose molecules into biochemically useful smaller molecule.

In order that the present invention may be more readily understood, certain terms are first defined herein.

The term "pentose phosphosphate biosynthetic pathway" includes the biosynthetic pathway involving pentose phosphate biosynthetic genes, enzymes (*e.g.*, polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of fine chemicals, *e.g.*, lysine. The term "pentose phosphosphate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of fine chemicals, *e.g.*, lysine, in a microorganisms (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of fine chemicals, *e.g.*, lysine, *in vitro*.

The term "pentose phosphosphate biosynthetic pathway protein" or "pentose phosphosphate biosynthetic pathway enzyme" includes a those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly or indirectly involved in the pentose phosphosphate biosynthetic pathway, *e.g.*, the glycerol kinase enzyme.

The term "pentose phosphosphate biosynthetic pathway gene" includes a those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes which are directly or indirectly involved in the pentose phosphosphate biosynthetic pathway, *e.g.*, the glycerol kinase gene.

The term "amino acid biosynthetic pathway gene" is meant to include those genes and gene fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly involved in the synthesis of amino acids, *e.g.*, glycerol kinase. These genes may be identical to those which naturally occur within a host cell and are involved in the synthesis of any amino acid, and particularly lysine, within that host cell.

The term "lysine biosynthetic pathway gene" includes those genes and genes fragments encoding peptides, polypeptides, proteins, and enzymes, which are directly or indirectly involved in the synthesis of lysine, *e.g.*, glycerol kinase. These genes can be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such genes, for example, the genes can contain modifications or mutations which do not significantly affect the biological activity of the encoded protein. For example, the natural gene can be modified by mutagenesis or by introducing or

substituting one or more nucleotides or by removing nonessential regions of the gene. Such modifications are readily performed by standard techniques.

5 The term "lysine biosynthetic pathway protein" is meant to include those peptides, polypeptides, proteins, enzymes, and fragments thereof which are directly involved in the synthesis of lysine. These proteins can be identical to those which naturally occur within a host cell and are involved in the synthesis of lysine within that host cell. Alternatively, there can be modifications or mutations of such proteins, for example, the proteins can contain modifications or mutations which do not significantly affect the biological activity of the protein. For example, the natural protein can be modified by mutagenesis or by introducing or substituting one or more amino acids, preferably by conservative amino acid substitution, or by removing nonessential regions of the protein. Such modifications are readily performed by standard techniques. Alternatively, lysine biosynthetic proteins can be heterologous to the particular host cell. Such proteins can be from any organism having genes encoding proteins having the same, or similar, biosynthetic roles.

15 The term, "carbon flux" refers to the number of glucose molecules which proceed down a particular metabolic path relative to competing paths. In particular, increased NADPH within a microorganism is achieved by altering the carbon flux distribution between the glycolytic and pentose phosphate pathways of that organism.

20 "Glycerol kinase activity" includes any activity exerted by a glycerol kinase protein, polypeptide or nucleic acid molecule as determined *in vivo*, or *in vitro*, according to standard techniques. Glycerol kinase is involved in many different metabolic pathways and found in many organisms. Preferably, a glycerol kinase activity includes the catalysis of ATP and glycerol to ADP and glycerol 3-phosphate.

25 The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described *e.g.* in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (*e.g.*, arachidonic acid), diols (*e.g.*, propane diol, and butane diol), carbohydrates (*e.g.*, hyaluronic acid and trehalose), aromatic compounds (*e.g.*, aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and

Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCs Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), and all other chemicals described in Gutcho (1983) *Chemicals by Fermentation*, Noyes Data Corporation, ISBN:

- 5 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.

Amino Acid Metabolism and Uses

- Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term “amino acid” is art-recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann’s *Encyclopedia of Industrial Chemistry*, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins. Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. *Biochemistry*, 3rd edition, pages 578-590 (1988)). The ‘essential’ amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 ‘nonessential’ amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.

- Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L-methionine are common feed additives. (Leuchtenberger, W. (1996) *Amino acids – technical production and use*, p. 466-502 in Rehm *et al.* (eds.) *Biotechnology* vol. 6,

chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of α -ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transfer of the side-chain β -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. *Biochemistry* 3rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. *Biochemistry*, 3rd ed. Ch. 24: "Biosynthesis of

Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

Vitamin, Cofactor, and Nutraceutical Metabolism and Uses

5 Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of
10 metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-
15 recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention
20 are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of
25 Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research –
30 Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).

Thiamin (vitamin B₁) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B₂) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5'-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The
35 family of compounds collectively termed 'vitamin B₆' (e.g., pyridoxine, pyridoxamine, pyridoxa-5'-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-β-alanine) can be

produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of β -alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β -alanine and for the condensation to panthothenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5'-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B₅), pantetheine (and its derivatives) and coenzyme A.

Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α -ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5'-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.

Corrinoids (such as the cobalamines and particularly vitamin B₁₂) and porphyrines belong to a group of chemicals characterized by a tetrapyrrole ring system. The biosynthesis of vitamin B₁₂ is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known.

Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.

The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B₆, pantothenate, and biotin. Only Vitamin B₁₂ is produced solely by fermentation, due to the complexity of its synthesis. *In vitro* methodologies require significant inputs of materials and time, often at great cost.

Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses

Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (i.e., AMP) or as coenzymes (i.e., FAD and NAD).

Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of *de novo* pyrimidine and purine biosynthesis as chemotherapeutic agents." *Med. Res. Reviews* 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." *Curr. Opin. Struct. Biol.* 5: 752-757; (1995) *Biochem Soc. Transact.* 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) *Nucleotides and Related Compounds in Biotechnology* vol. 6, Rehm *et al.*, eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.

The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) "*de novo* purine nucleotide biosynthesis", in: *Progress in Nucleic Acid Research and Molecular Biology*, vol. 42, Academic Press, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides", Chapter 8 in: *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York). Purine metabolism has been the subject of

intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'-phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5'-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.

15 *Trehalose Metabolism and Uses*

Trehalose consists of two glucose molecules, bound in α, α -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto *et al.*, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) *Trends Biotech.* 16: 460-467; Paiva, C.L.A. and Panek, A.D. (1996) *Biotech. Ann. Rev.* 2: 293-314; and Shiosaka, M. (1997) *J. Japan* 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.

25

I. Recombinant Microorganisms and Methods for Culturing Microorganisms Such That A Fine Chemical is Produced

The methodologies of the present invention feature microorganisms, *e.g.*, recombinant microorganisms, preferably including vectors or genes (*e.g.*, wild-type and/or mutated genes) as described herein and/or cultured in a manner which results in the production of a desired fine chemical, *e.g.*, lysine. The term "recombinant" microorganism includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) which has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived. Preferably, a "recombinant" microorganism of the present invention has been genetically engineered such that it underexpresses at least one bacterial gene or

35

gene product as described herein, preferably a biosynthetic enzyme encoding-gene, *e.g.*, glycerol kinase, included within a recombinant vector as described herein and/or a biosynthetic enzyme, *e.g.*, glycerol kinase expressed from a recombinant vector. The ordinary skilled will appreciate that a microorganism expressing or underexpressing a gene product produces or underproduces the gene product as a result of underexpression of nucleic acid sequences and/or genes encoding the gene product. In one embodiment, the recombinant microorganism has decreased biosynthetic enzyme, *e.g.*, glycerol kinase, activity.

The term "manipulated microorganism" includes a microorganism that has been engineered (*e.g.*, genetically engineered) or modified such that results in the disruption or alteration of a metabolic pathway so as to cause a change in the metabolism of carbon. An enzyme is "underexpressed" in a metabolically engineered cell when the enzyme is expressed in the metabolically engineered cell at a lower level than the level at which it is expressed in a comparable wild-type cell, including, but not limited to, situations where there is no expression at all. Underexpression of the gene may lead to decreased activity of the protein encoded by the gene, *e.g.*, glycerol kinase.

Modification or engineering of such microorganisms can be according to any methodology described herein including, but not limited to, deregulation of a biosynthetic pathway and/or underexpression of at least one biosynthetic enzyme. A "manipulated" enzyme (*e.g.*, a "manipulated" biosynthetic enzyme) includes an enzyme, the expression or production of which has been altered or modified such that at least one upstream or downstream precursor, substrate or product of the enzyme is altered or modified, *e.g.*, has decreased activity, for example, as compared to a corresponding wild-type or naturally occurring enzyme.

The term "underexpressed" or "underexpression" includes expression of a gene product (*e.g.*, a pentose phosphate biosynthetic enzyme) at a level lower than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically manipulated (*e.g.*, genetically engineered) to express a level of gene product at a lesser level than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. Genetic manipulation can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by removing strong promoters, inducible promoters or multiple promoters), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site or transcription terminator, decreasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription

of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, or other methods to knock-out or block expression of the target protein).

5 In another embodiment, the microorganism can be physically or environmentally manipulated to express a level of gene product lower than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to decrease transcription of a
10 particular gene and/or translation of a particular gene product such that transcription and/or translation are decreased. Alternatively, a microorganism can be cultured at a temperature selected to decrease transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are decreased.

The term "deregulated" or "deregulation" includes the alteration or
15 modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is decreased, thereby decreasing the activity of the gene product. The phrase "deregulated
20 pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism arises from the particular phenomenon
25 of microorganisms in which more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon".

The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more,
30 preferably at least two, structural genes (*e.g.*, genes encoding enzymes, for example, biosynthetic enzymes). Expression of the structural genes can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The structural genes can be transcribed to give a single mRNA that encodes all of the structural proteins. Due to the coordinated regulation of
35 genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of each gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding

strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, decreasing the copy
5 number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor
10 proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

A particularly preferred "recombinant" microorganism of the present invention has been genetically engineered to underexpress a bacterially-derived gene or
15 gene product. The term "bacterially-derived" or "derived-from", for example bacteria, includes a gene which is naturally found in bacteria or a gene product which is encoded by a bacterial gene (e.g., encoded by glycerol kinase).

The methodologies of the present invention feature recombinant microorganisms which underexpress one or more genes, e.g., the glycerol kinase gene or
20 have decreased the glycerol kinase activity. A particularly preferred recombinant microorganism of the present invention (e.g., *Corynebacterium glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum*, and *Corynebacterium thermoaminogenes*, etc.) has been genetically engineered to underexpress a biosynthetic enzyme (e.g., glycerol kinase, the amino acid sequence of
25 SEQ ID NO:2 or encoded by the nucleic acid sequence of SEQ ID NO:1).

Other preferred "recombinant" microorganisms of the present invention have an enzyme deregulated in the pentose phosphate pathway. The phrase
"microorganism having a deregulated pentose phosphate pathway" includes a microorganism having an alteration or modification in at least one gene encoding an
30 enzyme of the pentose phosphate pathway or having an alteration or modification in an operon including more than one gene encoding an enzyme of the pentose phosphate pathway. A preferred "microorganism having a deregulated pentose phosphate pathway" has been genetically engineered to underexpress a *Corynebacterium* (e.g., *C. glutamicum*) biosynthetic enzyme (e.g., has been engineered to underexpress glycerol
35 kinase).

In another preferred embodiment, a recombinant microorganism is designed or engineered such that one or more pentose phosphate biosynthetic enzyme is underexpressed or deregulated.

In another preferred embodiment, a microorganism of the present invention underexpresses or is mutated for a gene or biosynthetic enzyme (e.g., a pentose phosphate biosynthetic enzyme) which is bacterially-derived. The term "bacterially-derived" or "derived-from", for example bacteria, includes a gene product
5 (e.g., glycerol kinase) which is encoded by a bacterial gene.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive microorganism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a
10 microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Corynebacterium*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Corynebacterium glutamicum*, *Corynebacterium*
15 *acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the recombinant microorganism is *Corynebacterium glutamicum*.

An important aspect of the present invention involves culturing the recombinant microorganisms described herein, such that a desired compound (e.g., a
20 desired fine chemical) is produced. The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (e.g., maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a
25 microorganism of the invention is cultured in media (e.g., a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism. Carbon sources which may be used include sugars and carbohydrates, such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as for example soy oil, sunflower oil, peanut oil and
30 coconut oil, fatty acids, such as for example palmitic acid, stearic acid and linoleic acid, alcohols, such as for example glycerol and ethanol, and organic acids, such as for example acetic acid. In a preferred embodiment, fructose or sucrose are used as carbon sources. These substances may be used individually or as a mixture.

Nitrogen sources which may be used comprise organic compounds
35 containing nitrogen, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya flour and urea or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate. The nitrogen sources may be used individually or as a mixture. Phosphorus

sources which may be used are phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding salts containing sodium. The culture medium must furthermore contain metal salts, such as for example magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such as amino acids and vitamins may also be used in addition to the above-stated substances. Suitable precursors may furthermore be added to the culture medium. The stated feed substances may be added to the culture as a single batch or be fed appropriately during cultivation.

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art. For example, basic compounds such as sodium hydroxide, potassium hydroxide, ammonia, or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used to appropriately control the pH of the culture.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (*e.g.*, oxygen) to result in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the growth vessel (*e.g.*, fermentor) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (*e.g.*, through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents such as fatty acid polyglycol esters).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired fine chemical, *e.g.*, lysine. In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 45°C or between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired fine chemical, *e.g.*, lysine. A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired fine chemical, *e.g.*, lysine is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired fine chemical or to obtain desired yields of the particular fine chemical, *e.g.*, lysine, being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a fine chemical (*e.g.*, lysine). Preferably, culturing is continued for a time sufficient to substantially reach maximal production of the fine chemical. In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In another embodiment, culturing is continued for a time sufficient to reach production yields of a fine chemical, for example, cells are cultured such that at least about 15 to 20 g/L of a fine chemical are produced, at least about 20 to 25 g/L of a fine chemical are produced, at least about 25 to 30 g/L of a fine chemical are produced, at least about 30 to 35 g/L of a fine chemical are produced, at least about 35 to 40 g/L of a fine chemical are produced, at least about 40 to 50 g/L of a fine chemical are produced, at least about 50 to 60 g/L of a fine chemical are produced, at least about 60 to

70 g/L of a fine chemical are produced, at least about 70 to 80 g/L of a fine chemical are produced, at least about 80 to 90 g/L of a fine chemical are produced, at least about 90 to 100 g/L of a fine chemical are produced, at least about 100 to 110 g/L of a fine chemical are produced, at least about 110 to 120 g/L of a fine chemical are produced, at least about 120 to 130 g/L of a fine chemical are produced, at least about 130 to 140 g/L of a fine chemical are produced, or at least about 140 to 160 g/L of a fine chemical are produced. In yet another embodiment, microorganisms are cultured under conditions such that a preferred yield of a fine chemical, for example, a yield within a range set forth above, is produced in about 24 hours, in about 36 hours, in about 40 hours, in about 48 hours, in about 72 hours, in about 96 hours, in about 108 hours, in about 122 hours, or in about 144 hours.

The methodology of the present invention can further include a step of recovering a desired fine chemical, *e.g.*, lysine. The term "recovering" a desired fine chemical, *e.g.*, lysine includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a fine chemical, *e.g.*, lysine, can be recovered from culture media by first removing the microorganisms from the culture. Media is then passed through or over a cation exchange resin to remove unwanted cations and then through or over an anion exchange resin to remove unwanted inorganic anions and organic acids having stronger acidities than the fine chemical of interest (*e.g.*, lysine).

Preferably, a desired fine chemical of the present invention is "extracted", "isolated" or "purified" such that the resulting preparation is substantially free of other components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other components" includes preparations of desired compound in which the compound is separated (*e.g.*, purified or partially purified) from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of

other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (e.g., less than about 1-2% other media components or fermentation byproducts).

5 In an alternative embodiment, the desired fine chemical, e.g., lysine, is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (e.g., safe). For example, the entire culture (or culture supernatant) can be used as a source of product (e.g., crude product). In one embodiment, the culture (or culture supernatant) supernatant is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

II. Methods of Producing A Fine Chemical Independent of Precursor Feed Requirements

15 Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (e.g., feed) microorganisms of the present invention at least one pentose phosphase pathway biosynthetic precursor such that fine chemicals, e.g., lysine, are produced. The term "pentose phosphase pathway biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase pentose phosphate biosynthesis. In one embodiment, the pentose phosphate biosynthetic precursor or precursor is glucose. In another embodiment, the pentose phosphate biosynthetic precursor is fructose. The amount of glucose or fructose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (e.g., a concentration sufficient to enhance production of a fine chemical e.g., lysine). Pentose phosphate biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (e.g., in a suitable solvent such as water or buffer) or in the form of a solid (e.g., in the form of a powder). Moreover, pentose phosphate biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

35 Providing pentose phosphate biosynthetic precursors in the pentose phosphate biosynthetic methodologies of the present invention, can be associated with high costs, for example, when the methodologies are used to produce high yields of a fine chemical. Accordingly, preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes (e.g., at least one pentose phosphate biosynthetic enzyme) manipulated such

that lysine or other desired fine chemicals are produced in a manner independent of precursor feed. The phrase "a manner independent of precursor feed", for example, when referring to a method for producing a desired compound includes an approach to or a mode of producing the desired compound that does not depend or rely on precursors being provided (*e.g.*, fed) to the microorganism being utilized to produce the desired compound. For example, microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requiring no feeding of the precursors glucose or fructose.

Alternative preferred methodologies of the present invention feature microorganisms having at least one biosynthetic enzyme or combination of biosynthetic enzymes manipulated such that lysine or other fine chemicals are produced in a manner substantially independent of precursor feed. The phrase "a manner substantially independent of precursor feed" includes an approach to or a method of producing the desired compound that depends or relies to a lesser extent on precursors being provided (*e.g.*, fed) to the microorganism being utilized. For example, microorganisms featured in the methodologies of the present invention can be used to produce fine chemicals in a manner requiring feeding of substantially reduced amounts of the precursors glucose or fructose.

Preferred methods of producing desired fine chemicals in a manner independent of precursor feed or alternatively, in a manner substantially independent of precursor feed, involve culturing microorganisms which have been manipulated (*e.g.*, designed or engineered, for example, genetically engineered) such that expression of at least one pentose phosphate biosynthetic enzyme is modified. For example, in one embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that the production of at least one pentose phosphate biosynthetic enzyme is deregulated. In a preferred embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that it has a deregulated biosynthetic pathway, for example, a deregulated pentose phosphate biosynthesis pathway, as defined herein. In another preferred embodiment, a microorganism is manipulated (*e.g.*, designed or engineered) such that at least one pentose phosphate biosynthetic enzyme, *e.g.*, glycerol kinase is underexpressed.

III. High Yield Production Methodologies

A particularly preferred embodiment of the present invention is a high yield production method for producing a fine chemical, *e.g.*, lysine, comprising culturing a manipulated microorganism under conditions such that lysine is produced at a significantly high yield. The phrase "high yield production method", for example, a high yield production method for producing a desired fine chemical, *e.g.*, lysine, includes a method that results in production of the desired fine chemical at a level which

is elevated or above what is usual for comparable production methods. Preferably, a high yield production method results in production of the desired compound at a significantly high yield. The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (e.g., production of the product at a commercially feasible cost). In one embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 2 g/L, 10 g/L, 15 g/L, 20 g/L, 25 g/L, 30 g/L, 35 g/L, 40 g/L, 45 g/L, 50 g/L, 55 g/L, 60 g/L, 65 g/L, 70 g/L, 75 g/L, 80 g/L, 85 g/L, 90 g/L, 95 g/L, 100 g/L, 110 g/L, 120 g/L, 130 g/L, 140 g/L, 150 g/L, 160 g/L, 170 g/L, 180 g/L, 190 g/L, or 200 g/L.

The invention further features a high yield production method for producing a desired fine chemical, e.g., lysine, that involves culturing a manipulated microorganism under conditions such that a sufficiently elevated level of compound is produced within a commercially desirable period of time. In an exemplary embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 15-20 g/L in 5 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 25-40 g/L in 10 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 50-100 g/L in 20 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 140-160 g/L in 40 hours, for example, greater than 150 g/L in 40 hours. In another embodiment, the invention features a high yield production method of producing lysine that includes culturing a manipulated microorganism under conditions such that lysine is produced at a level greater than 130-160 g/L in 40 hours, for example, greater than 135, 145 or 150 g/L in 40 hours. Values and ranges included and/or intermediate within the ranges set forth herein are also intended to be within the scope of the present invention. For example, lysine production at levels of at least 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, and 150 g/L in 40 hours are intended to be included within the range of 140-150 g/L in 40 hours. In another example, ranges of 140-145 g/L or 145-150 g/L are intended to be included within the range of 140-150 g/L in 40 hours. Moreover, the skilled artisan will appreciate that culturing a manipulated microorganism to achieve a

production level of, for example, "140-150 g/L in 40 hours" includes culturing the microorganism for additional time periods (e.g., time periods longer than 40 hours), optionally resulting in even higher yields of lysine being produced.

5 IV. Isolated Nucleic Acid Molecules and Genes

Another aspect of the present invention features isolated nucleic acid molecules that encode proteins (e.g., *C. glutamicum* proteins), for example, *Corynebacterium* pentose phosphate biosynthetic enzymes (e.g., *C. glutamicum* pentose phosphate enzymes) for use in the methods of the invention. In one embodiment, the isolated nucleic acid molecules used in the methods of the invention are glycerol kinase nucleic acid molecules.

The term "nucleic acid molecule" includes DNA molecules (e.g., linear, circular, cDNA or chromosomal DNA) and RNA molecules (e.g., tRNA, rRNA, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The term "isolated" nucleic acid molecule includes a nucleic acid molecule which is free of sequences which naturally flank the nucleic acid molecule (i.e., sequences located at the 5' and 3' ends of the nucleic acid molecule) in the chromosomal DNA of the organism from which the nucleic acid is derived. In various embodiments, an isolated nucleic acid molecule can contain less than about 10 kb, 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the nucleic acid molecule in chromosomal DNA of the microorganism from which the nucleic acid molecule is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular materials when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

The term "gene," as used herein, includes a nucleic acid molecule (e.g., a DNA molecule or segment thereof), for example, a protein or RNA-encoding nucleic acid molecule, that in an organism, is separated from another gene or other genes, by intergenic DNA (i.e., intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). A gene may direct synthesis of an enzyme or other protein molecule (e.g., may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. Individual genes contained within an operon may overlap without intergenic DNA between said individual genes. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the

gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or distinct protein or RNA molecule, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Corynebacterium* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Corynebacterium* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Corynebacterium* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

In one aspect, the methods of the present invention features use of isolated glycerol kinase nucleic acid sequences or genes.

In a preferred embodiment, the nucleic acid or gene is derived from *Corynebacterium* (*e.g.*, is *Corynebacterium*-derived). The term "derived from *Corynebacterium*" or "*Corynebacterium*-derived" includes a nucleic acid or gene which is naturally found in microorganisms of the genus *Corynebacterium*. Preferably, the nucleic acid or gene is derived from a microorganism selected from the group consisting of *Corynebacterium glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the nucleic acid or gene is derived from *Corynebacterium glutamicum* (*e.g.*, is *Corynebacterium glutamicum*-derived). In yet another preferred embodiment, the nucleic acid or gene is a *Corynebacterium* gene homologue (*e.g.*, is derived from a species distinct from *Corynebacterium* but having significant homology to a *Corynebacterium* gene of the present invention, for example, a *Corynebacterium* glycerol kinase gene).

Included within the scope of the present invention are bacterial-derived nucleic acid molecules or genes and/or *Corynebacterium*-derived nucleic acid molecules or genes (*e.g.*, *Corynebacterium*-derived nucleic acid molecules or genes), for example, the genes identified by the present inventors, for example, *Corynebacterium* or *C. glutamicum* glycerol kinase genes. Further included within the scope of the present invention are bacterial-derived nucleic acid molecules or genes and/or *Corynebacterium*-derived nucleic acid molecules or genes (*e.g.*, *C. glutamicum*-derived nucleic acid molecules or genes) (*e.g.*, *C. glutamicum* nucleic acid molecules or genes) which differ from naturally-occurring bacterial and/or *Corynebacterium* nucleic acid molecules or genes (*e.g.*, *C. glutamicum* nucleic acid molecules or genes), for

example, nucleic acid molecules or genes which have nucleic acids that are substituted, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention. In one embodiment, an isolated nucleic acid molecule comprises the nucleotide sequences set forth as SEQ ID NO:1, or
 5 encodes the amino acid sequence set forth in SEQ ID NO:2.

In another embodiment, an isolated nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 60-65%, preferably at least about 70-75%, more preferable at least about 80-85%, and even more preferably at least about 90-95% or more identical to a nucleotide sequence set forth as SEQ ID
 10 NO:1. In another embodiment, an isolated nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence set forth as SEQ ID NO:1. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent (*e.g.* high stringency)
 15 hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid
 20 molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature.

A nucleic acid molecule of the present invention (*e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1) can be isolated using standard molecular biology techniques and the sequence information provided herein. For
 25 example, nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) or can be isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based
 30 upon the sequence of SEQ ID NO:1. A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ
 35 ID NO:1.

In another embodiment, an isolated nucleic acid molecule is or includes a glycerol kinase gene, or portion or fragment thereof. In one embodiment, an isolated glycerol kinase nucleic acid molecule or gene comprises the nucleotide sequence as set

forth in SEQ ID NO:1 (e.g., comprises the *C. glutamicum* glycerol kinase nucleotide sequence). In another embodiment, an isolated glycerol kinase nucleic acid molecule or gene comprises a nucleotide sequence that encodes the amino acid sequence as set forth in SEQ ID NO:2 (e.g., encodes the *C. glutamicum* glycerol kinase amino acid sequence). In yet another embodiment, an isolated glycerol kinase nucleic acid molecule or gene encodes a homologue of the glycerol kinase protein having the amino acid sequence of SEQ ID NO:2. As used herein, the term "homologue" includes a protein or polypeptide sharing at least about 30-35%, preferably at least about 35-40%, more preferably at least about 40-50%, and even more preferably at least about 60%, 70%, 80%, 90% or more identity with the amino acid sequence of a wild-type protein or polypeptide described herein and having a substantially equivalent functional or biological activity as said wild-type protein or polypeptide. For example, a glycerol kinase homologue shares at least about 30-35%, preferably at least about 35-40%, more preferably at least about 40-50%, and even more preferably at least about 60%, 70%, 80%, 90% or more identity with the protein having the amino acid sequence set forth as SEQ ID NO:2 and has a substantially equivalent functional or biological activity (i.e., is a functional equivalent) of the protein having the amino acid sequence set forth as SEQ ID NO:2 (e.g., has a substantially equivalent pantothenate kinase activity). In a preferred embodiment, an isolated glycerol kinase nucleic acid molecule or gene comprises a nucleotide sequence that encodes a polypeptide as set forth in SEQ ID NO:2. In another embodiment, an isolated glycerol kinase nucleic acid molecule hybridizes to all or a portion of a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO:1 or hybridizes to all or a portion of a nucleic acid molecule having a nucleotide sequence that encodes a polypeptide having the amino acid sequence of SEQ ID NOs:2. Such hybridization conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions can be found in *Molecular Cloning: A Laboratory Manual*, Sambrook *et al.*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), chapters 7, 9 and 11. A preferred, non-limiting example of stringent hybridization conditions includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A preferred, non-limiting example of highly stringent hybridization conditions includes hybridization in 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A preferred, non-limiting example of reduced stringency hybridization conditions includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X SSC plus 50% formamide at about 40-45°C) followed

by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, *e.g.*, at 65-70°C or at 42-50°C are also intended to be encompassed by the present invention. SSPE (1X SSPE is 0.15 M NaCl, 10mM NaH₂PO₄, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1X SSC is 0.15 M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, $T_m(^{\circ}\text{C}) = 2(\# \text{ of A} + \text{T bases}) + 4(\# \text{ of G} + \text{C bases})$. For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G} + \text{C}) - (600/\text{N})$, where N is the number of bases in the hybrid, and $[\text{Na}^+]$ is the concentration of sodium ions in the hybridization buffer ($[\text{Na}^+]$ for 1X SSC = 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (*e.g.*, BSA or salmon or herring sperm carrier DNA), detergents (*e.g.*, SDS), chelating agents (*e.g.*, EDTA), Ficoll, PVP and the like. When using nylon membranes, in particular, an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in 0.25-0.5M NaH₂PO₄, 7% SDS at about 65°C, followed by one or more washes at 0.02M NaH₂PO₄, 1% SDS at 65°C, see *e.g.*, Church and Gilbert (1984) *Proc. Natl. Acad. Sci. USA* 81:1991-1995, (or, alternatively, 0.2X SSC, 1% SDS). In another preferred embodiment, an isolated nucleic acid molecule comprises a nucleotide sequence that is complementary to a glycerol kinase nucleotide sequence as set forth herein (*e.g.*, is the full complement of the nucleotide sequence set forth as SEQ ID NO:1).

A nucleic acid molecule of the present invention (*e.g.*, a glycerol kinase nucleic acid molecule or gene), can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, nucleic acid molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) or can be isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based upon the glycerol kinase nucleotide sequences set forth herein, or flanking sequences thereof. A nucleic acid of the invention (*e.g.*, a glycerol kinase nucleic acid molecule or gene), can be amplified using cDNA, mRNA or alternatively, chromosomal DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.

Yet another embodiment of the present invention features mutant glycerol kinase nucleic acid molecules or genes. The phrase "mutant nucleic acid molecule" or "mutant gene" as used herein, includes a nucleic acid molecule or gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein that may be encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Preferably, a mutant nucleic acid molecule or mutant gene (*e.g.*, a mutant glycerol kinase gene) encodes a polypeptide or protein having an increased activity (*e.g.*, having an increased glycerol kinase activity) as compared to the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can have a decreased level of production of the wild-type polypeptide.

As used herein, a "decreased activity" or "decreased enzymatic activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "decreased activity" or "decreased enzymatic activity" also includes an activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene). Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein isolated or purified from a cell. Alternatively, an activity can be measured or assayed within a cell or in an extracellular medium.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant nucleic acid or mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue, as described above, in that a mutant nucleic acid or mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or nucleic acid or producing said mutant protein or polypeptide (*i.e.*, a

mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid or producing said mutant protein or polypeptide. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding microorganism expressing the wild-type gene or nucleic acid. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (e.g., 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

V. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include nucleic acid molecules and/or genes described herein (e.g., isolated nucleic acid molecules and/or genes), preferably *Corynebacterium* genes; more preferably *Corynebacterium glutamicum* genes, even more preferably *Corynebacterium glutamicum* glycerol kinase genes.

The present invention further features vectors (e.g., recombinant vectors) that include nucleic acid molecules (e.g., isolated or recombinant nucleic acid molecules and/or genes) described herein. In particular, recombinant vectors are featured that include nucleic acid sequences that encode bacterial gene products as described herein, preferably *Corynebacterium* gene products, more preferably *Corynebacterium glutamicum* gene products (e.g., pentose phosphate enzymes, for example, glycerol kinase).

The term "recombinant nucleic acid molecule" includes a nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated nucleic acid molecule or gene of the present invention (e.g., an isolated glycerol kinase gene) operably linked to regulatory sequences.

The term "recombinant vector" includes a vector (e.g., plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which

the recombinant vector was derived. Preferably, the recombinant vector includes a glycerol kinase gene or recombinant nucleic acid molecule including such glycerol kinase gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs).

5 The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the nucleic acid molecule or gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (*e.g.*, enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the nucleotide sequence, preferably expression of a gene product encoded by the nucleotide
10 sequence (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

 The term "regulatory sequence" includes nucleic acid sequences which affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences. In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule
15 or recombinant vector in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to the gene
20 of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences, for example, to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included
25 in a recombinant nucleic acid molecule or recombinant vector operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

 In one embodiment, a regulatory sequence is a non-native or non-
30 naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational
35 regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include

those which direct constitutive expression of a nucleotide sequence in a microorganism (e.g., constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (e.g., inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (e.g., attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the regulation of transcription such that increased or constitutive transcription occurs can be removed such that expression of a gene of interest is decreased.

In one embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a pentose phosphate biosynthetic enzyme, for example glycerol kinase) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Corynebacterium* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Corynebacterium*). In one embodiment, a promoter is a *Corynebacterium* promoter, preferably a strong *Corynebacterium* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Corynebacterium* or a promoter associated with a glycolytic pathway gene in *Corynebacterium*). In another embodiment, a promoter is a bacteriophage promoter.

In another embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences). The term "terminator sequences" includes regulatory sequences which serve to terminate transcription of a gene. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (e.g., by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule or recombinant vector of the present invention includes sequences which allow for detection of the vector containing said sequences (i.e., detectable and/or selectable markers), for example, sequences that overcome auxotrophic mutations, for example, *ura3* or *ilvE*, fluorescent markers, and/or colorimetric markers (e.g., *lacZ*/ β -galactosidase), and/or antibiotic resistance genes (e.g., *amp* or *tet*).

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance genes. The term "antibiotic resistance genes" includes sequences which promote or confer resistance to antibiotics on the host organism (e.g., *Bacillus*). In one embodiment, the antibiotic resistance genes are selected from the group consisting of *cat* (chloramphenicol resistance) genes, *tet* (tetracycline resistance)

genes, *erm* (erythromycin resistance) genes, *neo* (neomycin resistance) genes and *spec* (spectinomycin resistance) genes. Recombinant vectors of the present invention can further include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *amyE* sequences can be used as homology targets for recombination into the host chromosome.

It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

VI. Isolated Proteins

Another aspect of the present invention features isolated proteins (e.g., isolated pentose phosphate biosynthetic enzymes, for example isolated glycerol kinase). In one embodiment, proteins (e.g., isolated pentose phosphate enzymes, for example isolated glycerol kinase) are produced by recombinant DNA techniques and can be isolated from microorganisms of the present invention by an appropriate purification scheme using standard protein purification techniques. In another embodiment, proteins are synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein (e.g., an isolated or purified biosynthetic enzyme) is substantially free of cellular material or other contaminating proteins from the microorganism from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, an isolated or purified protein has less than about 30% (by dry weight) of contaminating protein or chemicals, more preferably less than about 20% of contaminating protein or chemicals, still more preferably less than about 10% of contaminating protein or chemicals, and most preferably less than about 5% contaminating protein or chemicals.

In a preferred embodiment, the protein or gene product is derived from *Corynebacterium* (e.g., is *Corynebacterium*-derived). The term "derived from *Corynebacterium*" or "*Corynebacterium*-derived" includes a protein or gene product which is encoded by a *Corynebacterium* gene. Preferably, the gene product is derived from a microorganism selected from the group consisting of *Corynebacterium glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum* or *Corynebacterium thermoaminogenes*. In a particularly preferred embodiment, the protein or gene product is derived from *Corynebacterium glutamicum* (e.g., is *Corynebacterium glutamicum*-derived). The term "derived from *Corynebacterium glutamicum*" or "*Corynebacterium glutamicum*-derived" includes a protein or gene product which is encoded by a *Corynebacterium glutamicum* gene. In yet another

preferred embodiment, the protein or gene product is encoded by a *Cornynebacterium* gene homologue (e.g., a gene derived from a species distinct from *Cornynebacterium* but having significant homology to a *Cornynebacterium* gene of the present invention, for example, a *Cornynebacterium* glycerol kinase gene).

5 Included within the scope of the present invention are bacterial-derived proteins or gene products and/or *Cornynebacterium*-derived proteins or gene products (e.g., *C. glutamicum*-derived gene products) that are encoded by naturally-occurring bacterial and/or *Cornynebacterium* genes (e.g., *C. glutamicum* genes), for example, the genes identified by the present inventors, for example, *Cornynebacterium* or *C.*
10 *glutamicum* glycerol kinase genes. Further included within the scope of the present invention are bacterial-derived proteins or gene products and/or *Cornynebacterium*-derived proteins or gene products (e.g., *C. glutamicum*-derived gene products) that are encoded bacterial and/or *Cornynebacterium* genes (e.g., *C. glutamicum* genes) which differ from naturally-occurring bacterial and/or *Cornynebacterium* genes (e.g., *C.*
15 *glutamicum* genes), for example, genes which have nucleic acids that are mutated, inserted or deleted, but which encode proteins substantially similar to the naturally-occurring gene products of the present invention. For example, it is well understood that one of skill in the art can mutate (e.g., substitute) nucleic acids which, due to the degeneracy of the genetic code, encode for an identical amino acid as that encoded by
20 the naturally-occurring gene. Moreover, it is well understood that one of skill in the art can mutate (e.g., substitute) nucleic acids which encode for conservative amino acid substitutions. It is further well understood that one of skill in the art can substitute, add or delete amino acids to a certain degree without substantially affecting the function of a gene product as compared with a naturally-occurring gene product, each instance of
25 which is intended to be included within the scope of the present invention.

In a preferred embodiment, an isolated protein of the present invention (e.g., an isolated pentose phosphate biosynthetic enzyme, for example isolated glycerol kinase) has an amino acid sequence shown in SEQ ID NO:2. In other embodiments, an isolated protein of the present invention is a homologue of the protein set forth as SEQ
30 ID NO:2, (e.g., comprises an amino acid sequence at least about 30-40% identical, preferably about 40-50% identical, more preferably about 50-60% identical, and even more preferably about 60-70%, 70-80%, 80-90%, 90-95% or more identical to the amino acid sequence of SEQ ID NO:2, and has an activity that is substantially similar to that of the protein encoded by the amino acid sequence of SEQ ID NO:2.

35 To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). When a position in

the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions x 100), preferably taking into account the number of gaps and size of said gaps necessary to produce an optimal alignment.

The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Research* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (1988) *Comput Appl Biosci.* 4:11-17. Such an algorithm is incorporated into the ALIGN program available, for example, at the GENESTREAM network server, IGH Montpellier, FRANCE (<http://vega.igh.cnrs.fr>) or at the ISREC server (<http://www.ch.embnet.org>). When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

In another preferred embodiment, the percent homology between two amino acid sequences can be determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. In yet another preferred embodiment, the percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a gap weight of 50 and a length weight of 3.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents, Sequence Listing, Figures, and published patent applications cited throughout this application are incorporated herein by reference.

5

EXAMPLES

General Methodology:

Strains. *Corynebacterium glutamicum* ATCC 21526 was obtained from the American Type and Culture Collection (Manassas, USA). This homoserine auxotrophic strain excretes lysine during L-threonine limitation due to the bypass of concerted aspartate kinase inhibition. Precultures were grown in complex medium containing 5 g L⁻¹ of either fructose or glucose. For agar plates the complex medium was additionally amended with 12 g L⁻¹ agar. For the production of cells as inoculum for the tracer experiments and the tracer studies itself a minimal medium amended with 1 mg ml⁻¹ calcium panthotenate-HCl was used (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). In this medium concentrations of carbon source glucose or fructose, of the essential amino acids threonine, methionine and leucine and of citrate were varied as specified below.

Cultivation. Precultivation consisted of three steps involving (i) a starter cultivation in complex medium with cells from agar plate as inoculum, (ii) a short cultivation for adaption to minimal medium, and (iii) a prolonged cultivation on minimal medium with elevated concentrations of essential amino acids. Pre-cultures inoculated from agar plates were grown overnight in 100 ml baffled shake flasks on 10 ml complex medium. Afterwards cells were harvested by centrifugation (8800 g, 2 min, 30 °C), inoculated into minimal medium, and grown up to an optical density of 2 to obtain exponentially growing cells adapted to minimal medium. Afterwards cells were harvested by centrifugation (8800 g, 30 °C, and 2 min) including a washing step with sterile 0.9 % NaCl. They were then inoculated into 6 ml minimal medium in 50 ml baffled shake flasks with initial concentrations of 0.30 g L⁻¹ threonine, 0.08 g L⁻¹ methionine, 0.20 g L⁻¹ leucine, and 0.57 g L⁻¹ citrate. As carbon source 70 mM glucose or 80 mM fructose were added, respectively. Cells were grown until depletion of the essential amino acids, which was checked by HPLC analysis. At the end of the growth phase cells were harvested, and washed with sterile NaCl (0.9 %). Subsequently they were transferred into 4 ml minimal tracer medium in 25 ml baffled shake flasks for metabolic flux analysis under lysine producing conditions. The tracer medium did not contain any threonine, methionine, leucine and citrate. For each carbon source two

parallel flasks were incubated containing (i) 40 mM [$1\text{-}^{13}\text{C}$] labeled substrate, and (ii) 20 mM [$^{13}\text{C}_6$] labeled substrate plus 20 mM of naturally labeled substrate, respectively. All cultivations were carried out on a rotary shaker (Inova 4230, New Brunswick, Edison, NJ, USA) at 30°C and 150 rpm.

5 **Chemicals.** 99% [$1\text{-}^{13}\text{C}$] glucose, 99% [$1\text{-}^{13}\text{C}$] fructose, 99% [$^{13}\text{C}_6$] glucose and 99% [$^{13}\text{C}_6$] fructose were purchased from Campro Scientific (Veenendaal, Netherlands). Yeast extract and tryptone were obtained from Difco Laboratories (Detroit, Michigan USA). All other applied chemicals were from Sigma (St. Louis, MI USA), Merck (Darmstadt, Germany) or Fluka (Buchs, Switzerland), respectively, and of
10 analytical grade

Substrate and product analysis. Cell concentration was determined by measurement of cell density at 660 nm ($\text{OD}_{660\text{nm}}$) using a photometer (Marsha Pharmacia biotech, Freiburg, Germany) or by gravimetry. The latter was determined by harvesting 10 ml of cells from cultivation broth at room temperature for 10 min at 3700
15 g, including a washing step with water. Washed cells were dried at 80 °C until weight constancy. The correlation factor (g biomass/ $\text{OD}_{660\text{nm}}$) between dry cell dry mass and $\text{OD}_{660\text{nm}}$ was determined as 0.353.

 Concentrations of extracellular substrates and products were determined in cultivation supernatants, obtained via 3 min centrifugation at 16000 g. Fructose,
20 glucose, sucrose, and trehalose were quantified by GC after derivatization into oxime trimethylsilyl derivatives. For this purpose a HP 6890 gas chromatograph (Hewlett Packard, Palo Alto, USA) with an HP 5MS column (5 % phenyl-methyl-siloxane-diphenyldimethylpolysiloxane, 30 m x 250 μm , Hewlett Packard, Palo Alto, CA, USA), and a quadrupole mass selective detector with electron impact ionization at 70 eV
25 (Agilent Technologies, Waldbronn, Germany) was applied. Sample preparation included lyophilization of the culture supernatant, dissolution in pyridine, and subsequent two-step derivatization of the sugars with hydroxylamine and (trimethylsilyl)trifluoroacetamide (BSTFA) (Macherey & Nagel, Düren, Germany) (13, 14). $\beta\text{-D-ribose}$ was used as internal standard for quantification. The injected sample
30 volume was 0.2 μl . The time program for GC analysis was as follows: 150 °C (0 - 5 min), 8 °C min^{-1} (5 - 25 min), 310 °C (25 - 35 min). Helium was used as carrier gas with a flow of 1.5 l min^{-1} . The inlet temperature was 310 °C and the detector temperature was 320 °C. Acetate, lactate, pyruvate, 2-oxoglutarate, and dihydroxyacetone were determined by HPLC utilizing an Aminex-HPX-87H Biorad
35 Column (300 x 7.8 mm, Hercules, CA, USA) with 4 mM sulfuric acid as mobile phase at a flow rate of 0.8 ml min^{-1} , and UV-detection at 210 nm. Glycerol was quantified by enzymatic measurement (Boehringer, Mannheim, Germany). Amino acids were analyzed by HPLC (Agilent Technologies, Waldbronn, Germany) utilizing a Zorbax

Eclipse-AAA column (150 x 4.6 mm, 5 μ m, Agilent Technologies, Waldbronn Germany), with automated online derivatization (*o*-phthalaldehyde + 3-mercaptopropionic acid) at a flow rate of 2 ml min⁻¹, and fluorescence detection. Details are given in the instruction manual. α -amino butyrate was used as internal standard for quantification.

¹³C labeling analysis. The labeling patterns of lysine and trehalose in cultivation supernatants were quantified by GC-MS. Hereby single mass isotopomer fractions were determined. In the current work they are defined as M₀ (relative amount of non-labelled mass isotopomer fraction), M₁ (relative amount of single labelled mass isotopomer fraction) and corresponding terms for higher labelling. GC-MS analysis of lysine was performed after conversion into the t-butyl-dimethylsilyl (TBDMS) derivate as described previously (Rubino, F. M. 1989. J. Chromatogr. 473:125-133). Quantification of mass isotopomer distributions was performed in selective ion monitoring (SIM) mode for the ion cluster *m/z* 431-437. This ion cluster corresponds to a fragment ion, which is formed by loss of a t-butyl group from the derivatization residue, and thus includes the complete carbon skeleton of lysine (Wittmann, C., M. Hans and E. Heinzle. 2002. Analytical Biochem. 307:379-382). The labeling pattern of trehalose was determined from its trimethylsilyl (TMS) derivate as described previously (Wittmann, C., H. M. Kim and E. Heinzle. 2003. Metabolic flux analysis at miniaturized scale. submitted). The labeling pattern of trehalose was estimated via the ion cluster at *m/z* 361-367 corresponding to a fragment ion that contained an entire monomer unit of trehalose and thus a carbon skeleton equal to that of glucose 6-phosphate. All samples were measured first in scan mode therewith excluding isobaric interference between analyzed products and other sample components. All measurements by SIM were performed in duplicate. The experimental errors of single mass isotopomer fractions in the tracer experiments on fructose were 0.85 % (M₀), 0.16 % (M₁), 0.27 % (M₂), 0.35 % (M₃), 0.45 % (M₄) for lysine on [1-¹³C] fructose, 0.87 % (M₀), 0.19 % (M₁), 0.44 % (M₂), 0.45 % (M₃), 0.88 % (M₄) for trehalose on [1-¹³C] fructose, and 0.44 % (M₀), 0.54 % (M₁), 0.34 % (M₂), 0.34 % (M₃), 0.19 % (M₄), 0.14 % (M₅) and 0.52 % (M₆) for trehalose on 50 % [¹³C₆] fructose, respectively. The experimental errors of MS measurements in glucose tracer experiments were 0.47 % (M₀), 0.44 % (M₁), 0.21 % (M₂), 0.26 % (M₃), 0.77 % (M₄) for lysine on [1-¹³C] glucose, 0.71 % (M₀), 0.85 % (M₁), 0.17 % (M₂), 0.32 % (M₃), 0.46 % (M₄) for trehalose on [1-¹³C] glucose, and 1.29 % (M₀), 0.50 % (M₁), 0.83 % (M₂), 0.84 % (M₃), 1.71 % (M₄), 1.84 % (M₅) and 0.58 % (M₆) for trehalose on 50 % [¹³C₆] glucose, respectively.

Metabolic modelling and parameter estimation. All metabolic simulations were carried out on a personal computer. Metabolic network of lysine-producing *C. glutamicum* was implemented in Matlab 6.1 and Simulink 3.0 (Mathworks,

Inc., Natick, MA USA). The software implementation included an isotopomer model in Simulink to calculate the ^{13}C labeling distribution in the network. For parameter estimation the isotopomer model was coupled with an iterative optimization algorithm in Matlab. Details on the applied computational tools are given by Wittmann and Heinzle (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859).

The metabolic network was based on previous work and comprised glycolysis, pentose phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, anaplerotic carboxylation of pyruvate, biosynthesis of lysine and other secreted products (Tab. 1), and anabolic fluxes from intermediary precursors into biomass. In addition uptake systems for glucose and fructose were alternatively implemented. Uptake of glucose involved phosphorylation to glucose 6-phosphate via a PTS (Ohnishi, J., S. Mitsuhashi, M. Hayashi, S. Ando, H. Yokoi, K. Ochiai and M. A. Ikeda. 2002. Appl. Microbiol. Biotechnol. 58:217-223). For fructose two uptake systems were considered: (i) uptake by $\text{PTS}_{\text{Fructose}}$ and conversion of fructose into fructose 1,6-bisphosphatase via fructose 1-phosphate and (ii) uptake by $\text{PTS}_{\text{Mannose}}$ leading to fructose 6-phosphate, respectively (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccain-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). In addition fructose-1,6-bisphosphatase was implemented into the model to allow carbon flux in both directions in the upper glycolysis. Reactions regarded reversible were transaldolase and transketolases in the PPP. Additionally glucose 6-phosphate isomerase was considered reversible for the experiments on glucose, whereby the trehalose labeling sensitively reflected the reversibility of this enzyme. In contrast the reversibility of glucose 6-phosphate isomerase could not be determined on fructose. In fructose-grown cells, glucose 6-phosphate is exclusively formed from fructose 6-phosphate leading to identical labeling patterns for the two pools. Therefore interconversion between glucose 6-phosphate and fructose 6-phosphate by a reversible glucose 6-phosphate isomerase does not result in labeling differences that could be used for the estimation of glucose 6-phosphate isomerase reversibility. The measured labeling of lysine and trehalose was not sensitive towards (i) the reversibility of the flux between the lumped pools of phosphoenolpyruvate/pyruvate and malate/oxaloacetate and (ii) the reversibility of malate dehydrogenase and fumarate hydratase in the TCA cycle. Accordingly these reactions were regarded irreversible. The labeling of alanine from a mixture of naturally labeled and $[^{13}\text{C}_6]$ labeled substrate, which is sensitive for these flux parameters, was not available in this study. Based on previous results the glyoxylate pathway was assumed to be inactive (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859).

Stoichiometric data on growth, product formation, and biomass composition of *C. glutamicum* together with mass spectrometric labeling data of secreted lysine and trehalose were used to calculate metabolic flux distributions. The set of fluxes that gave minimum deviation between experimental ($M_{i,exp}$) and simulated ($M_{i,calc}$) mass isotopomer fractions of lysine and trehalose of the two parallel experiments was taken as best estimate for the intracellular flux distribution. As described in the appendix the two networks of glucose-grown and fructose-grown cells were over determined. A least square approach was therefore possible. As error criterion a weighted sum of least squares (SLS) was used, where $S_{i,exp}$ is the standard deviation of the measurements (Eq. 1).

$$SLS = \sum_i \frac{(M_{i,exp} - M_{i,calc})^2}{S_{i,exp}^2} \quad (\text{Equation 1})$$

Multiple parameter initializations were applied to investigate whether an obtained flux distribution represented a global optimum. For all strains the glucose uptake flux during lysine production was set to 100 % and the other fluxes in the network are given as relative molar fluxes normalized to the glucose uptake flux.

Statistical evaluation. Statistical analysis of the obtained metabolic fluxes was carried out by a Monte-Carlo approach as described previously (Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). For each strain, the statistical analysis was carried out by 100 parameter estimation runs, whereby the experimental data, comprising measured mass isotopomer ratios and measured fluxes, were varied statistically. From the obtained data 90 % confidence limits for the single parameters were calculated.

EXAMPLE I: LYSINE PRODUCTION BY *C. GLUTAMICUM* ON FRUCTOSE AND GLUCOSE

Metabolic fluxes of lysine producing *C. glutamicum* were analyzed in comparative batch cultures on glucose and fructose. For this purpose pre-grown cells were transferred into tracer medium and incubated for about 5 hours. The analysis of substrates and products at the beginning and the end of the tracer experiment revealed drastic differences between the two carbon sources. Overall 11.1 mM lysine was produced on glucose, whereas a lower concentration of only 8.6 mM was reached on fructose. During the incubation over 5 hours, the cell concentration increased from 3.9 g L⁻¹ to 6.0 g L⁻¹ (glucose) and from 3.5 g L⁻¹ to 4.4 g L⁻¹ (fructose). Due to the fact that threonine and methionine were not present in the medium, internal sources were

probably utilized by the cells for biomass synthesis. The mean specific sugar uptake rate was higher on fructose (1.93 mmol g⁻¹ h⁻¹) compared to glucose (1.71 mmol g⁻¹ h⁻¹). As depicted in Table 1, the obtained yields of *C. glutamicum* ATCC 21526 differed drastically between fructose and glucose. This involved the main product lysine and various byproducts. Concerning lysine, the yield on fructose was 244 mmol mol⁻¹ and thus was lower compared to the yield on glucose (281 mmol mol⁻¹). Additionally the carbon source had a drastic influence on the biomass yield, which was reduced by almost 50% on fructose in comparison to glucose. The most significant influence of the carbon source on byproduct formation was observed for dihydroxyacetone, glycerol, and lactate. On fructose, accumulation of these byproducts was strongly enhanced. The yield for glycerol was 10 fold higher, whereas dihydroxyacetone and lactate secretion were increased by a factor of six. Dihydroxyacetone was the dominating byproduct on fructose. Due to the lower biomass yield a significantly reduced demand for anabolic precursors resulted for fructose-grown cells (Table 2).

Table 1: Biomass and metabolites in the stage of lysine production by *Corynebacterium glutamicum* ATCC 21526 from glucose (left) and fructose (right). Experimental yields are mean values of two parallel incubations on (i) 40 mM [1-¹³C] labeled substrate and (ii) 20 mM [¹³C₆] labeled substrate plus 20 mM naturally labeled substrate with corresponding deviations between the two incubations. All yields are given in (mmol product) (mol)⁻¹ except the yield for biomass, which is given in (mg of dry biomass) (mmol)⁻¹.

Yield	Lysine production on glucose	Lysine production on fructose
Biomass	54.1 ± 0.8	28.5 ± 0.0
Lysine	281.0 ± 2.0	244.4 ± 23.3
Valine	0.1 ± 0.0	0.0 ± 0.0
Alanine	0.1 ± 0.0	0.4 ± 0.1
Glycine	6.6 ± 0.0	7.1 ± 0.4
Dihydroxyacetone	26.3 ± 15.3	156.6 ± 25.8
Glycerol	3.8 ± 2.4	38.4 ± 3.9
Trehalose	3.3 ± 0.5	0.9 ± 0.1
α-Ketoglutarate	1.6 ± 0.4	6.5 ± 0.3
Acetate	45.1 ± 0.3	36.2 ± 5.7
Pyruvate	1.2 ± 0.4	2.1 ± 0.5
Lactate	7.1 ± 1.7	38.3 ± 3.5

Table 2. Anabolic demand of *Corynebacterium glutamicum* ATCC 21526 for intracellular metabolites in the stage of lysine production from glucose (left) and fructose (right). Experimental data are mean values of two parallel incubations on (i) [$1\text{-}^{13}\text{C}$] labeled substrate and (ii) a 1:1 mixture of naturally labeled and [$^{13}\text{C}_6$] substrate with deviation between the two incubations.

Precursor Demand* mmol (mol glucose) ⁻¹	Lysine production on glucose	Lysine production on fructose
Glucose 6-phosphate	11.09 ± 0.16	5.84 ± 0.05
Fructose 6-phosphate	3.84 ± 0.06	2.02 ± 0.02
Pentose 5-phosphate	47.50 ± 0.70	25.05 ± 0.21
Erythrose 4-phosphate	14.50 ± 0.22	7.64 ± 0.06
Glyceraldehyde 3-phosphate	6.98 ± 0.10	3.68 ± 0.03
3-Phosphoglycerate	59.95 ± 0.89	36.85 ± 0.31
Pyruvate/Phosphoenolpyruvate	107.80 ± 1.60	56.80 ± 0.48
α-Ketoglutarate	92.51 ± 1.37	48.73 ± 0.41
Oxaloacetate	48.91 ± 0.72	45.76 ± 0.38
Acetyl CoA	135.30 ± 2.00	71.25 ± 0.60
Diaminopimelate+Lysine**	18.83 ± 0.28	9.92 ± 0.08

*) The estimation of precursor demands was based on the experimental biomass yield obtained for each strain (Tab. 1) and the biomass composition previously measured for *C. glutamicum* (Marx, A., A. A. de Graaf, W. Wiechert, L. Eggeling and H. Sahm. 1996. Biotechnol. Bioeng. 49:111-129).

**) Diaminopimelate and lysine are regarded as separate anabolic precursors. This is due to the fact that anabolic fluxes from pyruvate and oxaloacetate into diaminopimelate (cell wall) and lysine (protein) contribute in addition to the flux of lysine secretion to the overall flux through the lysine biosynthetic pathway.

EXAMPLE II: MANUAL INSPECTION OF ^{13}C -LABELING PATTERNS IN TRACER EXPERIMENTS

Relative mass isotopomer fractions of secreted lysine and trehalose were quantified with GC-MS. These mass isotopomer fractions are sensitive towards intracellular fluxes and therefore display fingerprints for the fluxome of the investigated biological system. As shown in Figure 2, labeling patterns of secreted lysine and trehalose differed significantly between glucose and fructose-grown cells of *C. glutamicum*. The differences were found for both applied tracer labelings and for both measured products. This indicates substantial differences in the carbon flux pattern depending on the applied carbon source. As previously shown, mass isotopomer fractions from two parallel cultivations of *C. glutamicum* on a mixture of [$1\text{-}^{13}\text{C}$] and [$^{13}\text{C}_6$] glucose were almost identical (Wittmann, C., H. M. Kim and E. Heinzle. 2003).

Metabolic flux analysis at miniaturized scale. submitted). Therefore, the differences observed can be clearly related to substrate specific differences in metabolic fluxes.

5 **EXAMPLE III: ESTIMATION OF INTRACELLULAR FLUXES**

 A central issue of the performed studies was the comparative investigation of intracellular fluxes of *C. glutamicum* during lysine production on glucose and fructose as carbon source, respectively. For this purpose, the experimental data obtained from the tracer experiments were used to calculate metabolic flux
10 distributions for each substrate applying the flux estimation software as described above. The parameter estimation was carried out by minimizing the deviation between experimental and calculated mass isotopomer fractions. The performed approach utilized metabolite balancing during each step of the optimization. This included (i)
15 stoichiometric data on product secretion (Table 2) and (ii) stoichiometric data on anabolic demand for biomass precursors (Table 3). The set of intracellular fluxes that gave the minimum deviation between experimental and simulated labeling patterns was taken as best estimate for the intracellular flux distribution. For both scenarios, identical flux distributions were obtained with multiple initialization values, suggesting that
20 global minima were identified. Obviously, good agreement between experimentally determined and calculated mass isotopomer ratios was achieved (Table 4).

Table 3:

Relative mass isotopomer fractions of secreted lysine and trehalose of lysine producing *Corynebacterium glutamicum* ATCC 21526 cultivated on glucose and fructose, respectively. For both carbon sources two parallel tracer experiments on (i) $[1-^{13}\text{C}]$ labeled and (ii) a 1:1 mixture of naturally ^{13}C labeled and $[^{13}\text{C}_6]$ labeled tracer substrate were carried out. Experimental GC/MS data (exp) and values predicted by the solution of the mathematical model corresponding to the optimized set of fluxes (calc). M_0 denotes the relative amount of non-labelled mass isotopomer fraction, M_1 the relative amount of the single labelled mass isotopomer fraction, and corresponding terms stand for higher labelling

	Lysine (on [1- ¹³ C] labeled substrate)					Trehalose (on [1- ¹³ C] labeled substrate)					Trehalose (on 50 % [¹³ C ₆] labeled substrate)						
	M ₀	M ₁	M ₂	M ₃	M ₄	M ₀	M ₁	M ₂	M ₃	M ₄	M ₀	M ₁	M ₂	M ₃	M ₄	M ₅	M ₆
glucose exp calc	0.234	0.360	0.247	0.110	0.037	0.110	0.551	0.216	0.094	0.023	0.271	0.114	0.087	0.115	0.069	0.066	0.279
	0.242	0.355	0.245	0.110	0.037	0.114	0.549	0.212	0.094	0.023	0.268	0.113	0.085	0.113	0.068	0.064	0.289
fructose exp calc	0.133	0.316	0.304	0.162	0.062	0.212	0.412	0.244	0.092	0.030	0.141	0.103	0.104	0.250	0.133	0.110	0.159
	0.139	0.321	0.298	0.159	0.061	0.195	0.419	0.254	0.094	0.030	0.144	0.103	0.102	0.245	0.131	0.111	0.164

EXAMPLE IV: METABOLIC FLUXES ON FRUCTOSE AND GLUCOSE DURING LYSINE PRODUCTION

The obtained intracellular flux distributions for lysine-producing *C. glutamicum* on glucose and fructose are shown in Figs. (4, 5). Obviously, the intracellular fluxes differed tremendously depending on the carbon source applied. On glucose, 62 % of the carbon flux was directed towards the PPP, whereas only 36 % were channeled through the glycolytic chain (Fig. 4) Due to this a relatively high amount, 124 % NADPH was generated by the PPP enzymes glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. The situation on fructose was completely different (Fig. 5). The performed flux analysis revealed the *in vivo* activity of two PTS for uptake of fructose, whereby 92.3 % of fructose were taken up by fructose specific PTS_{Fructose}. A comparably small fraction of 7.7 % of fructose was taken up by PTS_{Mannose}. Thus, the majority of fructose entered the glycolysis at the level of fructose 1,6-bisphosphatase, whereas only a small fraction was channeled upstream at fructose 6-phosphate into the glycolytic chain. In comparison to glucose-grown cells, the PPP exhibited a dramatically reduced activity of only 14.4 %. Glucose 6-phosphate isomerase operated in opposite directions on the two carbon sources. In glucose-grown cells 36.2 % net flux were directed from glucose 6-phosphate to fructose 6-phosphate, whereas a backward net flux of 15.2 % was observed on fructose.

On fructose, the flux through glucose 6-phosphate isomerase and PPP was about twice as high as the flux through the PTS_{Mannose}. However this was not due to a gluconeogenic flux of carbon from fructose 1,6 bisphosphatase to fructose 6-phosphate, which could have supplied extra carbon flux towards the PPP. In fact flux through fructose 1,6-bisphosphatase catalyzing this reaction was zero. The metabolic reactions responsible for the additional flux towards the PPP are the reversible enzymes transaldolase and transketolase in the PPP. About 3.5 % of this additional flux was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway. Moreover 4.2 % of flux was directed towards fructose 6-phosphate and the PPP by the action of transaldolase.

Depending on the carbon source, completely different flux patterns in lysine producing *C. glutamicum* were also observed around the pyruvate node (Figs. 4, 5). On glucose the flux into the lysine pathway was 30.0 %, whereas a reduced flux of 25.4 % was found on fructose. The elevated lysine yield on glucose compared to fructose is the major reason for this flux difference, but also the higher biomass yield resulting in a higher demand for diaminopimelate for cell wall synthesis and lysine for protein synthesis contributes to it. The anaplerotic flux on glucose was 44.5 % and thus markedly higher compared to the flux on fructose (33.5 %). This is mainly due to the higher demand for oxaloacetate for lysine production, but also to the higher anabolic

demands for oxaloacetate and 2-oxoglutarate on glucose. On the other hand, flux through pyruvate dehydrogenase was substantially lower on glucose (70.9 %) compared to fructose (95.2 %). This reduced carbon flux into the TCA cycle resulted in more than 30 % reduced fluxes through TCA cycle enzymes on glucose (Figs. 3, 4).

- 5 Statistical evaluation of the obtained fluxes by a Monte-Carlo approach was used to calculate 90 % confidence intervals for the determined flux parameters. As shown for various key fluxes in Table 5, the confidence intervals were generally narrow. As example the confidence interval for the flux through glucose 6-phosphate dehydrogenase was only 1.2 % for glucose-grown and 3.5 % for fructose-grown cells.
- 10 The chosen approach therefore allowed precise flux estimation. It can be concluded that the flux differences observed on glucose and fructose, respectively, are clearly caused by the applied carbon source.

- It has to be noticed that the mean specific substrate uptake of 1.93 mmol g⁻¹ h⁻¹ on fructose was slightly higher than that of 1.77 mmol g⁻¹ h⁻¹ found on glucose.
- 15 Due to this the absolute intracellular fluxes expressed in mmol g⁻¹ h⁻¹ are slightly increased in relation to glucose compared to the relative fluxes discussed above. The flux distributions of lysine producing *C. glutamicum* on fructose and glucose, respectively, are however so completely different, that all comparisons drawn above also hold for absolute carbon fluxes.

20

- Table 4:** Statistical evaluation of metabolic fluxes of lysine producing *Corynebacterium glutamicum* ATCC 21526 grown on fructose (left) and glucose (right) determined by ¹³C tracer studies with mass spectrometry and metabolite balancing: 90 % confidence intervals of key flux parameters were obtained by a Monte-Carlo approach including 100 independent parameter estimation runs for each substrate with statistically varied experimental data.
- 25

Flux parameter	Glucose	Fructose
Net Flux		
fructose uptake by PTS _{Fre}	-	[90.0 96.1]
fructose uptake by PTS _{Man}	-	[3.9 10.0]
glucose 6-phosphate isomerase	[35.7 36.8]	[13.4 16.9]
phosphofructokinase	[35.7 36.8]	-
fructose 1,6-bisphosphatase	-	[-2.1 3.4]
fructose 1,6-bisphosphatase aldolase	[73.7 73.8]	[91.7 92.9]
glucose 6-phosphate dehydrogenase	[62.5 63.7]	[12.6 16.1]
transaldolase	[19.4 19.8]	[3.6 4.1]
transketolase 1	[19.4 19.8]	[3.6 4.1]
transketolase 2	[17.9 18.3]	[2.9 4.0]
glyceraldehyde 3-phosphate dehydrogenase	[158.1 164.5]	[163.3 174.6]
pyruvate kinase	[156.2 167.4]	[158.9 168.2]
pyruvate dehydrogenase	[69.5 72.5]	[87.1 102.3]
pyruvate carboxylase	[43.7 44.8]	[29.9 37.3]
citrate synthase	[51.2 54.8]	[76.5 91.5]
	[51.2 54.8]	[76.5 91.5]

isocitrate dehydrogenase	[41.6 45.6]	[70.9 86.0]
oxoglutarate dehydrogenase	[29.6 30.3]	[21.8 29.2]
aspartokinase		
Flux Reversibility**	[4.5 5.1]	-
glucose 6-phosphate isomerase	[4.3 4.9]	[14.5 18.2]
transaldolase	[0.0 0.0]	[0.0 0.1]
transketolase 1	[0.4 0.6]	[0.0 0.1]
transketolase 2		

* The negative flux for the lower confidence boundary is equal to a positive flux in the reverse direction (through phosphofructokinase).

** Flux reversibility is defined as ratio of back flux to net flux.

5

Discussion of Examples I- IV:

A. Substrate specific culture characteristics

- 10 Cultivation of lysine producing *C. glutamicum* on fructose and on glucose, respectively, revealed that growth and product formation strongly depend on the carbon source applied. Significantly reduced yields of lysine and biomass on fructose were previously also reported for another strain of *C. glutamicum*, where lysine and biomass yield were 30 % and 20 % less, respectively, compared to glucose (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43).
- 15 Cultivation of *C. glutamicum* and *C. melassecola* on fructose is linked to higher carbon dioxide production rates in comparison to glucose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccain-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102; Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). This coincides with the elevated flux through the TCA cycle observed in the present work for this carbon source. Substrate specific differences were also observed for byproducts. The formation of trehalose was lower on fructose compared to glucose. This may be related to different entry points of glucose and fructose into glycolysis (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). Considering the uptake systems in *C. glutamicum*, utilization of glucose leads to the formation of the trehalose precursor glucose 6-phosphate, whereas fructose is converted into fructose 1,6-bisphosphatase and thus enters the central metabolism downstream from glucose 6-phosphate (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccain-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). Other byproducts such as dihydroxyacetone, glycerol, and lactate were strongly increased, when fructose was applied as carbon source. From the viewpoint of lysine production, this is not desired, because a substantial fraction of carbon is withdrawn from the central metabolism into the formed byproducts. The specific substrate uptake on fructose ($1.93 \text{ mmol g}^{-1} \text{ h}^{-1}$) was

higher than on glucose ($1.77 \text{ mmol g}^{-1} \text{ h}^{-1}$). This result differs from a previous study on exponentially growing *C. melassecola* ATCC 17965 (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102), where similar specific uptake rates on fructose and glucose were observed. The higher uptake rate for fructose observed in our study might be due to the fact that the studied strains are different. *C. melassecola* and *C. glutamicum* are related species, but might differ in certain metabolic properties. The strain studied in the present work was previously derived by classical strain optimization. This could have introduced mutations influencing substrate uptake. Another explanation is the difference in cultivation conditions. Fructose might be more effectively utilized under conditions of limited growth and lysine production.

B. Metabolic flux distributions

The obtained intracellular flux distributions for lysine-producing *C. glutamicum* on glucose and fructose revealed tremendous differences. Statistical evaluation of the obtained fluxes revealed narrow 90% confidence intervals, so that the observed flux differences can be clearly attributed to the applied carbon sources. One of the most remarkable differences concerns the flux partitioning between glycolysis and PPP. On glucose 62.3 % of carbon was channeled through the PPP. The predominance of the PPP of lysine-producing *C. glutamicum* on this substrate has been previously observed in different studies (Marx, A., A. A. de Graaf, W. Wiechert, L. Eggeling and H. Sahm. 1996. Biotechnol. Bioeng. 49:111-129; Wittmann, C. and E. Heinzle. 2001. Eur. J. Biochem. 268:2441-2455; Wittmann, C. and E. Heinzle. 2002. Appl. Environ. Microbiol. 68:5843-5859). On fructose the flux into the PPP was reduced to 14.4 %. As identified by the performed metabolic flux analysis, this was mainly due to the unfavourable combination of the entry of fructose at the level of fructose 1,6-bisphosphatase and the inactivity of fructose 1,6 bisphosphatase. The observed inactivity of fructose 1,6 bisphosphatase agrees well with enzymatic measurements of *C. melassecola* ATCC 17965 during exponential growth on fructose and on glucose, respectively (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102).

Surprisingly, the flux through glucose 6-phosphate isomerase and PPP was about twice as high as the flux through the $\text{PTS}_{\text{Mannose}}$, when *C. glutamicum* was cultivated on fructose. Due to the inactivity of fructose 1,6 bisphosphatase this was not caused by a gluconeogenic flux. In fact, *C. glutamicum* possesses an operating metabolic cycle via fructose 6-phosphate, glucose 6-phosphate, and ribose 5-phosphate. Additional flux into the PPP was supplied by transketolase 2, which recycled carbon stemming from the PPP back into this pathway, and by the action of transaldolase,

which redirected glyceraldehyde 3-phosphate back into the PPP, thus bypassing gluconeogenesis. This cycling activity may help the cell to overcome NADPH limitation on fructose. The drastically reduced flux arriving at glucose 6-phosphate for fructose-grown *C. glutamicum* might also explain the reduced formation of trehalose on this substrate (Kiefer, P., E. Heinzle and C. Wittmann. 2002. J. Ind. Microbiol. Biotechnol. 28:338-43). Glucose 6-phosphate isomerase operated in opposite directions depending on the carbon source. In glucose-grown net flux was directed from glucose 6-phosphate to fructose 6-phosphate, whereas an inverse net flux was observed on fructose. This underlines the importance of the reversibility of this enzyme for metabolic flexibility in *C. glutamicum*.

C. NADPH metabolism

The following calculations provide a comparison of the NADPH metabolism of lysine producing *C. glutamicum* on fructose and glucose. The overall supply of NADPH was calculated from the estimated flux through glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and isocitrate dehydrogenase. On glucose, the PPP enzymes glucose 6-phosphate dehydrogenase (62.0 %) and glucose 6-phosphate dehydrogenase (62.0 %) supplied the major fraction of NADPH. Isocitrate dehydrogenase (52.9 %) contributed only to a minor extent. A completely different contribution of PPP and TCA cycle to NADPH supply was observed on fructose, where isocitrate dehydrogenase (83.3 %) was the major source for NADPH. Glucose 6-phosphate dehydrogenase (14.4 %) and glucose 6-phosphate dehydrogenase (14.4 %) produced much less NADPH on fructose. NADPH is required for growth and formation of lysine. The NADPH requirement for growth was calculated from a stoichiometric demand of $11.51 \text{ mmol NADPH (g biomass)}^{-1}$, which was assumed to be identical for glucose and fructose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102), and the experimental biomass yield of the present work (Tab. 1). *C. glutamicum* consumed 62.3 % of NADPH for biomass production on glucose, which was much higher as compared to fructose as carbon source (32.8 %). The amount of NADPH required for product synthesis was determined from the estimated flux into lysine (Tab. 1) and the corresponding stoichiometric NADPH demand of $4 \text{ mol (mol lysine)}^{-1}$. It was 112.4 % for lysine production from glucose and 97.6 % for lysine production from fructose. The overall NADPH supply on glucose was significantly higher (176.9 %) compared to fructose (112.1 %), which can be mainly attributed to the increased PPP flux on glucose. The NADPH balance was almost closed on glucose. In contrast a significant apparent deficiency for NADPH of 18.3 % was observed on fructose. This raises the question for enzymes catalyzing metabolic reactions that could supply NADPH in addition to the

above mentioned enzymes glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase and isocitrate dehydrogenase. A likely candidate seems NADPH-dependent malic enzyme. Previously an increased specific activity of this enzyme was detected on fructose-grown *C. melassecola* in comparison to glucose-grown cells (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). However, the flux through this particular enzyme could not be resolved by the experimental setup in the present work. Assuming malic enzyme as missing NADPH generating enzyme, a flux of 18.3 % would be sufficient to supply the apparently missing NADPH. Detailed flux studies of *C. glutamicum* with glucose as carbon source revealed no significant activity of malic enzyme (Petersen, S., A. A. de Graaf, L. Eggeling, M. Möllney, W. Wiechert and H. Sahm. 2000. J. Biol. Chem. 75:35932-35941). The situation on fructose might however be coupled to elevated *in vivo* activity of this enzyme.

15 D. NADH metabolism

On fructose *C. glutamicum* revealed increased activity of NADH forming enzymes. 421.2 % NADH were formed on fructose by glyceraldehyde 3-phosphate dehydrogenase, pyruvate dehydrogenase, 2-oxoglutarate dehydrogenase, and malate dehydrogenase. On glucose the NADH production was only 322.4 %. Additionally, the anabolic NADH demand was significantly lower on fructose than on glucose. The significantly enhanced NADH production coupled to a reduced metabolic demand could lead to an increased NADH/NAD ratio. For *C. melassecola* it was previously shown that fructose leads to increased NADH/NAD ratio compared to glucose (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102). This raises the question for NADH regenerating mechanisms during lysine production on fructose. Fructose-grown cells exhibited an enhanced secretion of dihydroxyacetone, glycerol, and lactate. The increased formation of dihydroxyacetone and glycerol could be due a higher NADH/NAD ratio. NADH was previously shown to inhibit glyceraldehyde dehydrogenase, so that overflow of dihydroxyacetone and glycerol might be related to a reduction of the flux capacity of this enzyme. The reduction of dihydroxyacetone to glycerol could additionally be favored by the high NADH/NAD ratio and thus contribute to regeneration of excess NADH. The NADH demanding lactate formation from pyruvate could have a similar background as the production of glycerol. In comparison to exponential growth, NADH excess under lysine producing conditions, characterized by relatively high TCA cycle activity and reduced biomass yield, might be even higher.

E. Potential targets for optimization of lysine-producing *C. glutamicum* on fructose

Based on the obtained flux patterns, several potential targets for the optimization of lysine production by *C. glutamicum* on fructose can be formulated. A central point is the supply of NADPH. Fructose 1,6 bisphosphatase is one target for increasing the supply of NADPH. Deregulation, e.g., amplification of its activity leads to a higher flux through the PPP, resulting in increased NADPH generation and increased lysine yield. An increase of the flux through the PPP via amplification of fructose 1,6-bisphosphatase is also be beneficial for aromatic amino acid production (Ikeda, M. 2003. Adv. Biochem. Eng. Biotechnol. 79: 1-36). The inactivity of fructose 1,6-bisphosphatase during growth on fructose is detrimental from the viewpoint of lysine production but not surprising, because this gluconeogenic enzyme is not required during growth on sugars and probably suppressed. In prokaryotes, this enzyme is under efficient metabolic control by e.g. fructose 1,6-bisphosphatase, fructose-2,6 bisphosphatase, metal ions and AMP (Skrypal, I. G. and O. V. Iastrebova. 2002. Mikrobiol Z. 64:82-94). It is known that *C. glutamicum* can grow on acetate (Wendisch, V. F., A. A. de Graaf, H. Sahm H. and B. Eikmans. 2000. J. Bacteriol. 182:3088-3096), where this enzyme is essential to maintain gluconeogenesis. Another potential target to increase the flux through the PPP is the PTS for fructose uptake. Modification of flux partitioning between PTS_{Fructose} and PTS_{Mannose} could yield a higher proportion of fructose, which enters at the level of fructose 6-phosphate and thus also lead to an increased PPP flux. Additionally amplification of malic enzyme that probably contributes significantly to NADPH supply on fructose could be an interesting target.

Another bottleneck comprises the strong secretion of dihydroxyacetone, glycerol, and lactate. The formation of dihydroxyacetone and glycerol could be blocked by deregulation, e.g., deletion of the corresponding enzymes. The conversion of dihydroxyacetone phosphate to dihydroxyacetone could be catalyzed by a corresponding phosphatase. A dihydroxyacetone phosphatase has however yet not been annotated in *C. glutamicum* (see the National Center for Biotechnology Information (NCBI) Taxonomy website: <http://www3.ncbi.nlm.nih.gov/Taxonomy/>). This reaction may be also catalyzed by a kinase, e.g., glycerol kinase. Currently two entries in the genome data base of *C. glutamicum* relate to dihydroxyacetone kinase (see the National Center for Biotechnology Information (NCBI) Taxonomy website: <http://www3.ncbi.nlm.nih.gov/Taxonomy/>).

Lactate secretion can also be avoided by deregulation, e.g., knockout of lactate dehydrogenase. Since glycerol and lactate formation could be important for NADH regeneration, negative effects on the overall performance of the organism can however not be excluded. In case carbon flux through the lower glycolytic chain is

limited by the capacity of glyceraldehyde 3-phosphate dehydrogenase as previously speculated (Dominguez, H., C. Rollin, A. Guyonvarch, J. L. Guerquin-Kern, M. Coccagn-Bousquet and N. D. Lindley. 1998. Eur. J. Biochem. 254:96-102), the suppression of dihydroxyacetone and glycerol production could eventually lead to an activation of fructose 1,6 bisphosphatase and a redirection of carbon flux through the PPP. It should be noticed that dihydroxyacetone is not reutilized during the cultivation of *C. glutamicum* and thus displays wasted carbon with respect to product synthesis, whereas this is not the case for lactate (Coccagn-Bousquet, M. and N. D. Lindley. 1995. Enz. Microbiol. Technol. 17:260-267).

In one embodiment, deregulation of one or more of the above genes in combination is useful in the production of a fine chemical, e.g., lysine.

In addition, sucrose is also useful as carbon source for lysine production by *C. glutamicum*, e.g., used in conjunction with the methods of the invention. Sucrose is the major carbon source in molasses. As shown previously, the fructose unit of sucrose enters glycolysis at the level of fructose 1,6-bisphosphatase (Dominguez, H. and N. D. Lindley. 1996. Appl. Environ. Microbiol. 62:3878-3880). Therefore this part of the sucrose molecule - assuming an inactive fructose 1,6-bisphosphatase - probably does not enter into the PPP, so that NADPH supply in lysine producing strains could be limited.

EXAMPLE V: CONSTRUCTION OF PLASMID PCIS LYSC

The first step of strain construction calls for an allelic replacement of the lysC wild-type gene in *C. glutamicum* ATCC13032. In it, a nucleotide replacement in the lysC gene is carried out, so that, the resulting protein, the amino acid Thr in position 311 is replaced by an Ile. Starting from the chromosomal DNA from ATCC13032 as template for a PCR reaction and using the oligonucleotide primers SEQ ID NO:3 and SEQ ID NO:4, lysC is amplified by use of the Pfu Turbo PCR system (Stratagene USA) in accordance with the instructions of the manufacturer. Chromosomal DNA from *C. glutamicum* ATCC 13032 is prepared according to Tauch et al. (1995) Plasmid 33:168-179 or Eikmanns et al. (1994) Microbiology 140:1817-1828. The amplified fragment is flanked at its 5' end by a SalI restriction cut and at its 3' end by a MluI restriction cut. Prior to the cloning, the amplified fragment is digested by these two restriction enzymes and purified using the GFX™ PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg).

SEQ ID NO:3

5'-GAGAGAGAGACGCGTCCCAGTGGCTGAGACGCATC -3'

SEQ ID NO:4

5'-CTCTCTCTGTCGACGAATTCAATCTTACGGCCTG-3'

The obtained polynucleotide is cloned through the SalI and MluI restriction cuts in pCLK5 MCS with integrated SacB, referred to in the following as pCIS (SEQ ID NO: 5) and transformed in *E. coli* XL-1 blue. A selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190). The plasmid is isolated and the expected nucleotide sequence is confirmed by sequencing. The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied Biosystems, Weiterstadt) and analyzed. The obtained plasmid pCIS lysC is listed as SEQ ID NO:6.

EXAMPLE VI: MUTAGENESIS OF THE LYSC GENE FROM *C. GLUTAMICUM*

The targeted mutagenesis of the lysC gene from *C. glutamicum* is carried out using the QuickChange Kit (Company: Stratagene/USA) in accordance with the instructions of the manufacturer. The mutagenesis is carried out in the plasmid pCIS lysC, SEQ ID NO:6. The following oligonucleotide primers are synthesized for the replacement of thr 311 by 311 ile by use of the QuickChange method (Stratagene):

SEQ ID NO:7

5'-CGGCACCACCGACATCATCTTCACCTGCCCTCGTTCCG -3'

SEQ ID NO:8

5'-CGGAACGAGGGCAGGTGAAGATGATGTCGGTGGTGCCG -3'

The use of these oligonucleotide primers in the QuickChange reaction leads, in the lysC gene SEQ ID NO:9, to the replacement of the nucleotide in position 932 (from C to T). The resulting amino acid replacement Thr311Ile in the lysC gene is confirmed, after transformation in *E. coli* XL1-blue and plasmid preparation, by [a] sequencing reactions. The plasmid is given the designation pCIS lysC thr311 ile and is listed as SEQ ID NO:10.

The plasmid pCIS lysC thr311ile is transformed in *C. glutamicum* ATCC13032 by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the lysC locus of individual transformants
5 is checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor. It is thereby established that the transformants involved are those that have integrated the transformed plasmid by homologous recombination at the lysC locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a
10 saccharose CM agar medium (10% saccharose) and incubated at 30°C for 24 hours. Because the sacB gene contained in the vector pCIS lysC thr311ile converts saccharose into a toxic product, only those colonies can grow that have deleted the sacB gene by a second homologous recombination step between the wild-type lysC gene and the mutated gene lysC thr311ile. During the homologous recombination, either the wild-
15 type gene or the mutated gene together with the sacB gene can be deleted. If the sacB gene together with the wild-type gene is removed, a mutated transformant results.

Growing colonies are picked and examined for a kanamycin-sensitive phenotype. Clones with deleted SacB gene must simultaneously show kanamycin-sensitive growth behavior. Such kanamycin-sensitive clones are investigated in a
20 shaking flask for their lysine productivity (see Example 6). For comparison, the non-treated *C. glutamicum* ATCC13032 is taken. Clones with an elevated lysine production in comparison to the control are selected, chromosomal DNA are recovered, and the corresponding region of the lysC gene is amplified by a PCR reaction and sequenced. One such clone with the property of elevated lysine synthesis and detected mutation in
25 lysC at position 932 is designated as ATCC13032 lysCfbr.

EXAMPLE VII: PREPARATION OF THE PLASMID PK19 MOB SACB DELTA GLYCEROL KINASE

30 Chromosomal DNA from *C. glutamicum* ATCC 13032 is prepared according to Tauch et al. (1995) Plasmid 33:168-179 or Eikmanns et al. (1994) Microbiology 140:1817-1828. With the oligonucleotide primers SEQ ID NO and SEQ ID NO:11 and 12, the chromosomal DNA as template, and Pfu Turbo polymerase (Company: Stratagene), the gene of glycerol kinase with flanking regions is amplified
35 by use of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.

SEQ ID NO:11

CK 345:

5'- GGCCGCTAGCGTTTTTGGTCACCCCGGAAT -3'

and

5 SEQ ID NO:12

CK 346:

5'- GGCTCTAGAACACGCTTGGACCAGTGCTT -3'

10 The obtained DNA fragment of approximately 2.4 [kb] size is purified using the GFX™ PCR DNA and Gel Band Purification Kit (Amersham Pharmacia, Freiburg) in accordance with the instructions of the manufacturer. Following this, it is cleaved using the restriction enzymes NheI and XbaI (Roche Diagnostics, Mannheim) and the DNA fragment is purified using the GFX™ PCR DNA and Gel Band Purification Kit.

15 The plasmid pK19 mob sacB SEQ ID NO:13 is also cut with the restriction enzymes NheI and XbaI and a fragment of 5.5 kb size is isolated, after electrophoretic separation, by use of the GFX™ PCR DNA and Gel Band Purification Kit.

20 The vector fragment is ligated together with the PCR fragment by use of the Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer and the ligation batch is transformed in competent E. coli XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)). A selection for plasmid-carrying cells is accomplished by plating out on
25 kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190). The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied
30 Biosystems, Weiterstadt) and analyzed. The resulting plasmid is designated as pK19 glycerol kinase.

The plasmid pK19 glycerol kinase (SEQ ID NO:14) is subsequently cut with the restriction enzymes BamHI and XhoI (Roche Diagnostics, Mannheim) and a fragment of 6.3 kb size is isolated, after electrophoretic separation, by use of the GFX™
35 PCR DNA and Gel Band Purification Kit. After a treatment of this fragment with the Klenow enzyme in accordance with the instructions of the manufacturer, the religation takes place by use of the Rapid DNA Ligation Kit (Roche Diagnostics, Mannheim) in accordance with the instructions of the manufacturer. The ligation batch is transformed

in competent *E. coli* XL-1 Blue (Stratagene, La Jolla, USA) according to standard methods, as described in Sambrook et al. (Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, (1989)). A selection for plasmid-carrying cells is accomplished by plating out on kanamycin (20 µg/mL) - containing LB agar (Lennox, 1955, Virology, 1:190).

The preparation of the plasmid DNA is carried out according to methods of and using materials of the company Qiagen. Sequencing reactions are carried out according to Sanger et al. (1977) Proceedings of the National Academy of Sciences USA 74:5463-5467. The sequencing reactions are separated by means of ABI Prism 377 (PE Applied Biosystems, Weiterstadt) and analyzed. The resulting plasmid pK19 delta glycerol kinase is listed as SEQ ID NO:15.

EXAMPLE VIII: PRODUCTION OF LYSINE

The plasmid pK19 delta glycerol kinase is transformed in *C. glutamicum* ATCC13032 *lysC^{fb}* by means of electroporation, as described in Liebl, et al. (1989) FEMS Microbiology Letters 53:299-303. Modifications of the protocol are described in DE 10046870. The chromosomal arrangement of the glycerol kinase locus of individual transformants are checked using standard methods by Southern blot and hybridization, as described in Sambrook et al. (1989), Molecular Cloning. A Laboratory Manual, Cold Spring Harbor. It may thereby be established that the transformants involve those that have integrated the transformed plasmid by homologous recombination at the glycerol kinase gene locus. After growth of such colonies overnight in media containing no antibiotic, the cells are plated out on a saccharose CM agar medium (10% saccharose) and incubated at 30°C for 24 hours.

Because the *sacB* gene contained in the vector pK19 delta glycerol kinase converts saccharose into a toxic product, only those colonies can grow that have deleted the *sacB* gene by a second homologous recombination step between the wild-type glycerol kinase gene and the shortened gene. During the homologous recombination, either the wild-type gene or the shortened gene together with the *sacB* gene can be deleted. If the *sacB* gene together with the wild-type gene is removed, a mutated transformant results.

Growing colonies are picked and examined for a kanamycin-sensitive phenotype. Clones with deleted *SacB* gene must simultaneously show kanamycin-sensitive growth behavior. Whether the desired replacement of the natural gene by the shortened gene has also taken place is checked by means of the polymerase chain reaction (PCR) according to standard methods, as described in Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press.. For this analysis,

chromosomal DNA from the starting strain and the resulting clones is isolated. To this end, the respective clones are removed from the agar plate with a toothpick and suspended in 100 μ L of H₂O and boiled up for 10 min at 95°C. In each case, 10 μ L of the resulting solution is used as template in the PCR. Used as primers are the

5 oligonucleotides CK345 und CK 346. A PCR product larger than in the case of a shortened gene is expected in the batch with the DNA of the starting strain owing to the choice of the oligonucleotide. A positive clone is designated as ATCC13032 Psod lysC^{fbr} delta glycerol kinase.

In order to investigate the effect of the delta glycerol kinase construct on

10 the lysine production, the strains ATCC13032, ATCC13032 lysC^{fbr}, and ATCC13032 lysC^{fbr} delta glycerol kinase are cultivated on CM plates (10.0 g/L D-glucose, 2.5 g/L NaCl, 2.0 g/L urea, 10.0 g/L bacto pepton (Difco), 5.0 g/L yeast extract (Difco), 5.0 g/L beef extract (Difco), 22.0 g/L agar (Difco), autoclaved (20 min. 121°C)) for 2 days at 30°C. Subsequently, the cells are scraped off the plate and resuspended in saline. For

15 the main culture, 10 mL of medium I and 0.5 g of autoclaved CaCO₃ (Riedel de Haen) are inoculated in a 100 mL Erlenmeyer flask with the cell suspension up to an OD₆₀₀ of 1.5 and incubated for 39 h on a [shaking incubator] of the type Infors AJ118 (Company: Infors, Bottmingen, Switzerland) at 220 rpm. Subsequently, the concentration of the lysine that separated out in the medium is determined.

20

Medium I:

40 g/L saccharose

60 g/L Molasses (calculated with respect to 100% sugar content)

10 g/L (NH₄)₂SO₄25 0.4 g/L MgSO₄*7H₂O0.6 g/L KH₂PO₄

0.3 mg/L thiamine*HCl

1 mg/L biotin (from a 1 mg/mL sterile-filtered stock solution that is adjusted with NH₄OH to pH 8.0)30 2 mg/L FeSO₄2 mg/L MnSO₄adjusted with NH₄OH to pH 7.8, autoclaved (121°C, 20 min).in addition, vitamin B12 (hydroxycobalamin Sigma Chemicals) from a stock solution (200 μ g/mL, sterile-filtered) is added up to a final concentration of 100 μ g/L.

35 The determination of the amino acid concentration is conducted by means of high pressure liquid chromatography according to Agilent on an Agilent 1100 Series LC System HPLC. A precolumn derivatization with ortho-phthalaldehyde permits

~~RGF-15000~~

the quantification of the amino acids that are formed; the separation of the amino acid mixture takes place on a Hypersil AA column (Agilent).

Moreover, the concentration of the side products glycerol and dihydroxyacetone is determined using an enzymatic test.

5

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the

5 following claims.

10

What is claimed:

1. A method for increasing metabolic flux through the pentose phosphate pathway
5 in a microorganism comprising culturing a microorganism comprising a gene which is
deregulated under conditions such that metabolic flux through the pentose phosphate
pathway is increased.
2. The method of claim 1, wherein fructose or sucrose is used as a carbon source.
- 10 3. The method of claim 1, wherein fructose is used as a carbon source.
4. The method of claim 1, wherein the gene is glycerol kinase.
- 15 5. The method of claim 4, wherein the glycerol kinase gene is derived from
Corynebacterium.
6. The method of claim 4, wherein the glycerol kinase gene is underexpressed.
- 20 7. The method of claim 1, wherein the gene encodes glycerol kinase.
8. The method of claim 7, wherein glycerol kinase has decreased activity.
9. The method of claim 1, wherein the microorganism is a Gram positive
25 microorganism.
10. The method of claim 1, wherein the microorganism belongs to the genus
Corynebacterium.
- 30 11. The method of claim 10, wherein the microorganism is *Corynebacterium*
glutamicum.
12. The method of claim 1, wherein the microorganism is fermented to produce a
fine chemical.
- 35 13. The method of claim 1, wherein the microorganism further comprises one or
more additional deregulated genes.

14. A method for producing a fine chemical comprising:
 - a) culturing a microorganism in which glycerol kinase is deregulated; and
 - b) accumulating the fine chemical in the medium or in the cells of the microorganisms, thereby producing a fine chemical.
15. A method for producing a fine chemical comprising culturing a microorganism in which at least one pentose phosphosphate biosynthetic pathway gene or enzyme is deregulated under conditions such that the fine chemical is produced.
16. The method of claim 15, wherein said biosynthetic gene is glycerol kinase.
17. The method of claim 15, wherein said biosynthetic enzyme is glycerol kinase.
18. The method of claim 16, wherein glycerol kinase expression is decreased.
19. The method of claim 17, wherein glycerol kinase activity is decreased.
20. The method of claim 14, further comprising recovering the fine chemical.
21. The method of claim 14 or 15, wherein the microorganism is a Gram positive microorganism.
22. The method of claim 14 or 15, wherein the microorganism belongs to the genus *Corynebacterium*.
23. The method of claim 22, wherein the microorganism is *Corynebacterium glutamicum*.
24. The method of claim 14, wherein glycerol kinase expression is decreased.
25. The method of claim 14, wherein glycerol kinase activity is decreased.
26. The method of claim 14 or 15, wherein the fine chemical is lysine.
27. The method of claim 26, wherein lysine is produced at a yield of at least 100 g/L.
28. The method of claim 26, wherein lysine is produced at a yield of at least 150 g/L.

29. The method of claim 14 or 15, wherein fructose or sucrose is used as a carbon source.
- 5 30. The method of claim 14 or 15, wherein fructose is used as a carbon source.
31. The method of claim 14 or 16, wherein glycerol kinase comprises the nucleotide sequence of SEQ ID NO:1.
- 10 32. The method of claim 14 or 16, wherein glycerol kinase encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
33. A recombinant microorganism which has a deregulated pentose phosphate biosynthesis pathway.
- 15 34. A recombinant microorganism comprising a deregulated pentose phosphate biosynthesis gene.
35. The recombinant microorganism of claim 34, wherein said deregulated gene is
- 20 glycerol kinase.
36. The recombinant microorganism of claim 35, wherein glycerol kinase expression is decreased.
- 25 37. The recombinant microorganism of claim 35, wherein said glycerol kinase gene encodes a glycerol kinase protein having decreased activity.
38. The recombinant microorganism of claim 34, wherein the microorganism belongs to the genus *Corynebacterium*.
- 30 39. The recombinant microorganism of claim 38, wherein the microorganism is *Corynebacterium glutamicum*.

METHODS FOR THE PREPARATION OF A
FINE CHEMICAL BY FERMENTATION

5

Abstract of the Disclosure

The present invention features methods of increasing the production of a fine chemical, *e.g.*, lysine from a microorganism, *e.g.*, *Corynebacterium* by way of deregulating an enzyme encoding gene, *i.e.*, glycerol kinase. In a preferred embodiment, the invention provides methods of increasing the production of lysine in

10 *Corynebacterium glutamicum* by way of increasing the expression of glycerol kinase activity. The invention also provides a novel process for the production of lysine by way of regulating carbon flux towards oxaloacetate (OAA). In a preferred embodiment, the invention provides methods for the production of lysine by way of utilizing fructose or

15 sucrose as a carbon source.





FIGURE 1

**FIGURE 2**




FIGURE 3




FIGURE 4




FIGURE 5

<110> BASF and University Saarbrücken et al.

<130> BGI-159PC

<170> FastSEQ for Windows Version 4.0

<211> 1650

<213> Corynebacterium glutamicum

<221> CDS

<222> (101) ... (1627)

```

accaaagcgcg acgcccgtgt agcagatgta ttggagtggg ggttctaata ggtgggtgta 60
aaacactgct tagtggccca atacgtgcaa aaataaggcc atg aga atc tca aag 115
Met Arg Ile Ser Lys
1 5

```

gcc aat gcg tat gtt gca gcg att gac caa ggc acc act tcc act cgg 163
Ala Asn Ala Tyr Val Ala Ala Ile Asp Gln Gly Thr Thr Ser Thr Arg
10 15 20

tgc atc ttc att gat gcc caa gga aaa gtg gtg tct tct gct tcc aag 211
Cys Ile Phe Ile Asp Ala Gln Gly Lys Val Val Ser Ser Ala Ser Lys
25 30 35

gag cac cgc caa atc ttc cca caa cag ggc tgg gta gag cac gat cct 259
Glu His Arg Gln Ile Phe Pro Gln Gln Gly Trp Val Glu His Asp Pro
40 45 50

gaa gaa att tgg gac aac att cga tct gtc gtc agc cag gcg atg gtc 307
Glu Glu Ile Trp Asp Asn Ile Arg Ser Val Val Ser Gln Ala Met Val
55 60 65

tcc att gac atc acc cca cac gag gtt gca tgc ctg gga gtc acc aac 355
Ser Ile Asp Ile Thr Pro His Glu Val Ala Ser Leu Gly Val Thr Asn
70 75 80 85

cag cgc gaa acc acc gtg gtg tgg gac aag cac acc ggc gaa cct gtc 403
Gln Arg Glu Thr Thr Val Val Trp Asp Lys His Thr Gly Glu Pro Val
90 95 100

tac aac gca atc gtg tgg caa gac acc cgc acc tct gac att tgc cta 451
Tyr Asn Ala Ile Val Trp Gln Asp Thr Arg Thr Ser Asp Ile Cys Leu
105 110 115

gag atc gcg ggc gaa gaa ggc cag gaa aag tgg ctt gac cgc acc ggc 499
Glu Ile Ala Gly Glu Glu Gly Gln Glu Lys Trp Leu Asp Arg Thr Gly.
120 125 130

BGI-159PC

ctg ctg atc aac tcc tac cca tcg ggg ccc aaa atc aag tgg att ctc Leu Leu Ile Asn Ser Tyr Pro Ser Gly Pro Lys Ile Lys Trp Ile Leu 135 140 145	547
gac aac gtt gag gga gct cgc gaa cgc gcc gaa aag ggc gac ctt ttg Asp Asn Val Glu Gly Ala Arg Glu Arg Ala Glu Lys Gly Asp Leu Leu 150 155 160 165	595
ttt ggc acc atg gat acc tgg gtg ctg tgg aac ctg acc ggc ggt gtc Phe Gly Thr Met Asp Thr Trp Val Leu Trp Asn Leu Thr Gly Gly Val 170 175 180	643
cgc ggc gac gac ggt gat gat gcc atc cac gtc acc gat gtc acc aac Arg Gly Asp Asp Gly Asp Asp Ala Ile His Val Thr Asp Val Thr Asn 185 190 195	691
gca tcc cgc aca cta ttg atg gat ctc cgc acg caa cag tgg gat cca Ala Ser Arg Thr Leu Leu Met Asp Leu Arg Thr Gln Gln Trp Asp Pro 200 205 210	739
gaa cta tgc gaa gcc cta gac att ccg atg tcc atg ctc cct gag att Glu Leu Cys Glu Ala Leu Asp Ile Pro Met Ser Met Leu Pro Glu Ile 215 220 225	787
cgt ccc tcc gtc gga gaa ttc cgc tcc gtg cgc cac cgc gga acc cta Arg Pro Ser Val Gly Glu Phe Arg Ser Val Arg His Arg Gly Thr Leu 230 235 240 245	835
gcc gac gtc ccg att act ggc gtg ctc ggc gac cag caa gcg gcc ctt Ala Asp Val Pro Ile Thr Gly Val Leu Gly Asp Gln Gln Ala Ala Leu 250 255 260	883
ttt ggt cag ggc gga ttc cac gaa ggt gct gct aaa aat acc tac ggc Phe Gly Gln Gly Gly Phe His Glu Gly Ala Ala Lys Asn Thr Tyr Gly 265 270 275	931
acc ggc ctc ttc ctg ctg atg aac acc ggc acc tcg ttg aag att tcc Thr Gly Leu Phe Leu Leu Met Asn Thr Gly Thr Ser Leu Lys Ile Ser 280 285 290	979
gag cac ggc ctg ctg tcc acc atc gcc tat caa cgg gaa gga tcc gct Glu His Gly Leu Leu Ser Thr Ile Ala Tyr Gln Arg Glu Gly Ser Ala 295 300 305	1027
ccg gtc tac gcg ctg gaa ggt tcc gta tcc atg ggc ggt tcc ttg gtg Pro Val Tyr Ala Leu Glu Gly Ser Val Ser Met Gly Gly Ser Leu Val 310 315 320 325	1075
cag tgg ctg cgc gac aac cta cag cta atc ccc aac gca cca gcg att Gln Trp Leu Arg Asp Asn Leu Gln Leu Ile Pro Asn Ala Pro Ala Ile 330 335 340	1123
gaa aac ctc gcc cga gaa gtc gaa gac aac ggt ggc gtt cat gtt gtc Glu Asn Leu Ala Arg Glu Val Glu Asp Asn Gly Gly Val His Val Val 345 350 355	1171
cca gca ttc acc gga ctg ttc gca cca cgt tgg cgc ccc gat gct cgt Pro Ala Phe Thr Gly Leu Phe Ala Pro Arg Trp Arg Pro Asp Ala Arg 360 365 370	1219

ggc gtc att aca ggc ctc acc cgt ttt gcc aac cgc aaa cac atc gcc 1267
 Gly Val Ile Thr Gly Leu Thr Arg Phe Ala Asn Arg Lys His Ile Ala
 375 380 385

cgc gca gtc ctt gaa gcc aac gcc ttc caa acc cgc gaa gtt gtg gac 1315
 Arg Ala Val Leu Glu Ala Asn Ala Phe Gln Thr Arg Glu Val Val Asp
 390 395 400 405

gcc atg gcc aaa gac gca ggc aaa gcc ctc gaa tcc ctc cgc gtc gac 1363
 Ala Met Ala Lys Asp Ala Gly Lys Ala Leu Glu Ser Leu Arg Val Asp
 410 415 420

ggt gcg atg gtg gaa aat gac ctc ctc atg caa atg caa gcc gac ttc 1411
 Gly Ala Met Val Glu Asn Asp Leu Leu Met Gln Met Gln Ala Asp Phe
 425 430 435

ctc ggc atc gac gtc caa cgt ctc gag gac gta gaa acc acc gcc gtc 1459
 Leu Gly Ile Asp Val Gln Arg Leu Glu Asp Val Glu Thr Thr Ala Val
 440 445 450

ggc gtc gca ttc gct gca ggt ctc ggc tct gga ttc ttc aaa aca act 1507
 Gly Val Ala Phe Ala Ala Gly Leu Gly Ser Gly Phe Phe Lys Thr Thr
 455 460 465

gac gag atc gaa aaa ctt att gca gtg aag aaa gtc tgg aac cct gac 1555
 Asp Glu Ile Glu Lys Leu Ile Ala Val Lys Lys Val Trp Asn Pro Asp
 470 475 480 485

atg agc gaa gaa gag cgc gaa cgt cgc tat gcc gaa tgg aat agg gca 1603
 Met Ser Glu Glu Glu Arg Glu Arg Arg Tyr Ala Glu Trp Asn Arg Ala
 490 495 500

gtg gag cat tct tat gac cag gcc tagctgattt gggtcggcct tta 1650
 Val Glu His Ser Tyr Asp Gln Ala
 505

<210> 2

<211> 509

<212> PRT

<213> Corynebacterium glutamicum

<400> 2

Met Arg Ile Ser Lys Ala Asn Ala Tyr Val Ala Ala Ile Asp Gln Gly
 1 5 10 15
 Thr Thr Ser Thr Arg Cys Ile Phe Ile Asp Ala Gln Gly Lys Val Val
 20 25 30
 Ser Ser Ala Ser Lys Glu His Arg Gln Ile Phe Pro Gln Gly Trp
 35 40 45
 Val Glu His Asp Pro Glu Glu Ile Trp Asp Asn Ile Arg Ser Val Val
 50 55 60
 Ser Gln Ala Met Val Ser Ile Asp Ile Thr Pro His Glu Val Ala Ser
 65 70 75 80
 Leu Gly Val Thr Asn Gln Arg Glu Thr Thr Val Val Trp Asp Lys His
 85 90 95
 Thr Gly Glu Pro Val Tyr Asn Ala Ile Val Trp Gln Asp Thr Arg Thr
 100 105 110
 Ser Asp Ile Cys Leu Glu Ile Ala Gly Glu Glu Gly Gln Glu Lys Trp
 115 120 125
 Leu Asp Arg Thr Gly Leu Leu Ile Asn Ser Tyr Pro Ser Gly Pro Lys
 130 135 140

RGL150DC

```

Ile Lys Trp Ile Leu Asp Asn Val Glu Gly Ala Arg Glu Arg Ala Glu
145                               150           155           160
Lys Gly Asp Leu Leu Phe Gly Thr Met Asp Thr Trp Val Leu Trp Asn
                               165           170           175
Leu Thr Gly Gly Val Arg Gly Asp Asp Gly Asp Asp Ala Ile His Val
                               180           185           190
Thr Asp Val Thr Asn Ala Ser Arg Thr Leu Leu Met Asp Leu Arg Thr
                               195           200           205
Gln Gln Trp Asp Pro Glu Leu Cys Glu Ala Leu Asp Ile Pro Met Ser
                               210           215           220
Met Leu Pro Glu Ile Arg Pro Ser Val Gly Glu Phe Arg Ser Val Arg
225                               230           235           240
His Arg Gly Thr Leu Ala Asp Val Pro Ile Thr Gly Val Leu Gly Asp
                               245           250           255
Gln Gln Ala Ala Leu Phe Gly Gln Gly Gly Phe His Glu Gly Ala Ala
                               260           265           270
Lys Asn Thr Tyr Gly Thr Gly Leu Phe Leu Leu Met Asn Thr Gly Thr
                               275           280           285
Ser Leu Lys Ile Ser Glu His Gly Leu Leu Ser Thr Ile Ala Tyr Gln
                               290           295           300
Arg Glu Gly Ser Ala Pro Val Tyr Ala Leu Glu Gly Ser Val Ser Met
305                               310           315           320
Gly Gly Ser Leu Val Gln Trp Leu Arg Asp Asn Leu Gln Leu Ile Pro
                               325           330           335
Asn Ala Pro Ala Ile Glu Asn Leu Ala Arg Glu Val Glu Asp Asn Gly
                               340           345           350
Gly Val His Val Val Pro Ala Phe Thr Gly Leu Phe Ala Pro Arg Trp
                               355           360           365
Arg Pro Asp Ala Arg Gly Val Ile Thr Gly Leu Thr Arg Phe Ala Asn
370                               375           380
Arg Lys His Ile Ala Arg Ala Val Leu Glu Ala Asn Ala Phe Gln Thr
385                               390           395           400
Arg Glu Val Val Asp Ala Met Ala Lys Asp Ala Gly Lys Ala Leu Glu
                               405           410           415
Ser Leu Arg Val Asp Gly Ala Met Val Glu Asn Asp Leu Leu Met Gln
                               420           425           430
Met Gln Ala Asp Phe Leu Gly Ile Asp Val Gln Arg Leu Glu Asp Val
                               435           440           445
Glu Thr Thr Ala Val Gly Val Ala Phe Ala Ala Gly Leu Gly Ser Gly
                               450           455           460
Phe Phe Lys Thr Thr Asp Glu Ile Glu Lys Leu Ile Ala Val Lys Lys
465                               470           475           480
Val Trp Asn Pro Asp Met Ser Glu Glu Glu Arg Glu Arg Arg Tyr Ala
                               485           490           495
Glu Trp Asn Arg Ala Val Glu His Ser Tyr Asp Gln Ala
                               500           505

```

<210> 3

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 3

gagagagaga cgcgtcccag tggctgagac gcac

35

<210> 4
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide

<400> 4
 ctctctctgt cgacgaattc aatcttacgg cctg

34

<210> 5
 <211> 4323
 <212> DNA
 <213> Corynebacterium glutamicum

<400> 5
 tcgagaggcc tgacgtcggg cccgggtacca cgcgtcatat gactagttcg gacctagggg 60
 tatcgtcgcac atcgatgctc ttctgcgtta attacaatt gggatcctct agacccggga 120
 tttaaatcgc tagcgggctg ctaaaggaag cggaacacgt agaaagccag tccgcagaaa 180
 cgggtgctgac cccggatgaa tgtcagctac tgggctatct ggacaaggga aaacgcaagc 240
 gcaaagagaa agcaggtagc ttgcagtggg cttacatggc gatagctaga ctgggcgggt 300
 ttatggacag caagcgaacc ggaattgccg gctggggcgc cctctggtaa gggtgggaag 360
 ccctgcaaag taaactggat ggctttcttg ccgccaagga tctgatggcg caggggatca 420
 agatctgac aagagacagg atgaggatcg ttctgcata ttgaacaaga tggattgcac 480
 gcaggttctc cggccgcttg ggtggagagg ctattcggct atgactgggc acaacagaca 540
 atcggctgct ctgatgcgc cgtgttccgg ctgtcagcgc aggggcgccc ggttcttttt 600
 gtcaagaccg acctgtccgg tgcctgaat gaactgcagg acgaggcagc gcggctatcg 660
 tggctggcca cgacgggcgt tccttgcgca gctgtgctcg acgttgtcac tgaagcggga 720
 agggactggc tgctattggg cgaagtgcg gggcaggatc tcctgtcatc tcaccttgct 780
 cctgccgaga aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgatccg 840

 gctacctgcc cattcgacca ccaagcgaaa catcgcacg agcgagcacg tactcggatg 900
 gaagccgggtc ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc 960
 gaactgttcg ccaggctcaa ggcgcgcatg cccgacggcg aggatctcgt cgtgacccat 1020
 ggcgatgcct gcttgccgaa tatcatgggt gaaaatggcc gcttttcttg attcatcgac 1080
 tgtggccggc tgggtgtggc ggaccgctat caggacatag cgttggtac ccgtgatatt 1140
 gctgaagagc ttggcggcga atgggctgac cgcttctctg tgccttacgg tatcgccgct 1200
 cccgattcgc agcgcacgc ctctatcgc ctcttgacg agttcttctg agcgggactc 1260
 tgggggttca aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca 1320
 ccgccgcctt ctatgaaagg ttgggcttcg gaatcgttt ccgggacgcc ggctggatga 1380
 tcctccagcg cggggatctc atgctggagt tcttcgccc cgctagcggc gcgccggcgc 1440
 gccgggtgtg aaataccgca cagatgcgta aggagaaaat accgcatcag gcgctcttc 1500
 gcttctctgc tcactgactc gctgcgctg gtcgttcggc tgcggcgagc ggtatcagct 1560
 cactcaaagg cggtaatacg gttatccaca gaactcaggg ataacgcagg aaagaacatg 1620
 tgagcaaaaagg gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 1680
 cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca gagtgggcga 1740
 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct 1800
 cctgttccga ccctgccgct taccggatac ctgtccgctt ttctcccttc gggaagcgtg 1860
 gcgctttctc atagctcacg ctgtaggatc ctcagttcgg tgtaggctcg tcgctccaag 1920
 ctgggctgtg tgcaagaacc ccccgcttcag cccgaccgct gcgccttate cggttaactat 1980
 cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac 2040
 aggattagca gagcgaggta tgtaggcggg gctacagagt tcttgaagtg gtggcctaac 2100
 tacgggtaca ctagaaggac agtatttggg atctgcgctc tgctgaagcc agttaccttc 2160
 ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggtttt 2220
 tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 2280
 ttttctacgg ggtctgacgc tcagtggaaac gaaaactcac gtttaaggat tttggtcatg 2340
 agattatcaa aaaggatctt cacctagatc cttttaaagg ccggcccgcg ccgccatcgg 2400
 cattttcttt tgcgttttta tttgttaact gttaattgtc cttgttcaag gatgctgtct 2460
 ttgacaacag atgttttctt gcctttgatg ttcagcagga agctcggcgc aaacgttgat 2520
 tgtttgtctg cgtagaatcc tctgtttgtc atatagcttg taatcacgac attgtttcct 2580

```

ttcgtttgag gtacagcgaa gtgtgagtaa gtaaaggtta catcgttagg atcaagatcc 2640
atttttaaca caaggccagt tttgttcagc ggcttgtatg ggccagttaa agaattagaa 2700
acataaccaa gcatgtaaat atcgtttagac gtaatgccgt caatcgtcac ttttgatccg 2760
cgggagtcag tgaacaggta ccatttgccg ttcatTTTTaa agacgttcgc gcgttcaatt 2820
tcatctgtta ctgtgttaga tgcaatcagc ggtttcatca cttttttcag tgtgtaata 2880
tcgttttagct caatcatacc gagagcgccg tttgctaact cagccgtgcg ttttttatcg 2940
ctttgcagaa gtttttgact ttcttgacgg aagaatgatg tgcttttgcc atagtatgct 3000
ttgttaaata aagattcttc gccttggtag ccatcttcag ttccagtgtt tgcttcaaat 3060
actaagtatt tgtggccttt atctctacg tagtgaggat ctctcagcgt atggttgctg 3120
cctgagctgt agttgccttc atcgatgaac tgctgtacat tttgatacgt ttttccgctca 3180
ccgtcaaaga ttgatttata atcctctaca ccgttgatgt tcaaagagct gtctgatgct 3240
gatacgttaa cttgtgcagt tgtcagtgtt tgtttgccgt aatgtttacc ggagaaatca 3300
gtgtagaata aacggatttt tccgtcagat gtaaatgtgg ctgaacctga ccattcttgt 3360
gtttggtctt ttaggataga atcatttgca tcgaatttgt cgctgtcttt aaagacgcgg 3420
ccagcgtttt tccagctgtc aatagaagtt tcgccgactt tttgatagaa catgtaaatc 3480
gatgtgtcat ccgcatTTTT cagtgccgtc agcgttttgt aatggccagc tgtccaaac 3540
tagtttgcaa cagtgccgtc agcgttttgt aatggccagc tgtccaaac 3600
tttgcaagag agatattttt aattgtggac gaatcaaatt cagaaacttg atatttttca 3660
tttttttgct gttcagggat ttgcagcata tcatggcgtg taatatggga aatgccgtat 3720
gtttccttat atggcttttg gttcgtttct ttcgcaaacg cttgagttgc gcctcctgcc 3780
agcagtgccg tagtaaagggt taatactggt gcttgTTTTg caaacttttt gatgttcac 3840
gttcatgtct ctttttttat gtactgtgtt agcggctctgc ttcttccagc cctcctgttt 3900
gaagatggca agttagttac gcacaataaa aaaagaccta aaatatgtaa ggggtgacgc 3960
caaagtatac actttgcctt ttacacattt taggtcttgc ctgctttatc agtaacaaac 4020
ccgcgcgatt tacttttcga cctcattcta ttagactctc gtttgatttg caactgggtc 4080
attttctctt tttgtttgat agaaaatcat aaaaggattt gcagactacg ggcctaaaga 4140
actaaaaaat ctatctgttt cttttcattc tctgtatttt ttatagtttc tgttgcatgg 4200
gcataaagtt gcctttttta tcacaattca gaaaatatca taatatctca tttcactaaa 4260
taatagtga cggcaggtat atgtgatggg ttaaaaagga tcggcggccg ctcgatttaa 4320
atc 4323

```

<210> 6

<211> 5860

<212> DNA

<213> Corynebacterium glutamicum

<400> 6

```

cccggtagca cgcgtcccag tggctgagac gcatccgcta aagccccagg aaccctgtgc 60
agaaagaaaa cactcctctg gctaggtaga cacagtttat aaaggtagag ttgagcgggt 120
aactgtcagc acgtagatcg aaagggtgcac aaagggtggc ctggctcgta agaaatatgg 180
cggttcctcg cttgagagtg cggaaacgcat tagaaacgtc gctgaacgga tcgttgccac 240

```

```

caagaaggct ggaaatgatg tctgtggttg ctgctccgca atgggagaca ccacggatga 300
acttctagaa cttgcagcgg cagtgaatcc cgttccgcca gctcgtgaaa tggatatgct 360
cctgactgct ggtgagcgta tttctaacgc tctcgtcgcc atggctattg agtcccttgg 420
cgcagaagcc caatctttca cgggctctca ggctgggtgtg ctcaccaccg agcggccacg 480
aaacgcacgc attgttgatg tcaactccagg tctgtgtcgt gaagcactcg atgagggcaa 540
gatctgcatt gttgctgggt tccagggtgt taataaagaa acccgcgatg tcaccacgtt 600
gggtcgtggg ggttctgaca ccactgcagt tgcgttggca gctgctttga acgtgatgt 660
gtgtgagatt tactcggacg ttgacgggtg gtataccgct gaccgcgca tcgttccctaa 720
tcacagaag ctggaaaagc tcagcttcga agaaatgctg gaacttgctg ctgttggttc 780
caagattttt gtgctgcgca gtgttgaata cgctcgtgca ttcaatgtgc cacttcgcgt 840
acgtcgtct ttagtaatg atccggcac tttgattgcc ggctctatgg aggatattcc 900
tgtggaagaa gcagtcctta ccgggtgtcg aaccgacaag tccgaagcca aagtaaccgt 960
tctgggtatt tccgataagc caggcgaggc tgcgaagggt ttccgtgcgt tggctgatgc 1020
agaaatcaac attgacatgg ttctgcagaa cgtctcttct gtagaagacg gcaccaccga 1080
catcaccttc acctgccctc gttccgacgg ccgcccgcg ttaggagatct tgaagaagct 1140
tcaggttcag ggcaactgga ccaatgtgct ttacgacgac caggctcgga aagctctcct 1200
cgtgggtgct ggcataaggt ctcaccacg tgttaccgca gagtcatgg aagctctgcg 1260
cgatgtcaac gtgaacatcg aattgatttc cactctgag attcgtattt ccgtgctgat 1320
ccgtgaagat gatctggatg ctgctgcacg tgcattgcat gagcagttcc agctgggcgg 1380

```

cgaagacgaa	gccgtcgttt	atgcaggcac	cggacgctaa	agttttaaag	gagtagtttt	1440
acaatgacca	ccatcgagct	tggtggtgca	accggccagg	tcggccagg	tatgcgcacc	1500
cttttggaa	agcgcaattt	cccagctgac	actgttcgtt	tctttgcttc	cccacgttcc	1560
gcaggccgta	agattgaatt	cgtcgacatc	gatgctcttc	tcggttaatt	aacaattggg	1620
atcctctaga	cccgggattt	aaatcgctag	cgggctgcta	aaggaagcgg	aacacgtaga	1680
aagccagtc	gcagaaacgg	tgctgacccc	ggatgaatgt	cagctactgg	gctatctgga	1740
caagggaaaa	cgcaagcgca	aagagaaagc	aggtagcttg	cagtgggctt	acatggcgat	1800
agctagactg	ggcggtttta	tggacagcaa	gcgaaccgga	attgccagct	ggggcgccct	1860
ctggtaaggt	tgggaagccc	tgcaaaagtaa	actggatggc	tttcttgccg	ccaaggatct	1920
gatggcgag	gggatcaaga	tctgatcaag	agacaggatg	aggatcggtt	cgcattgattg	1980
aacaagatgg	attgcacgca	ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	2040
actgggcaca	acagacaatc	ggctgctctg	atgccgcgt	gttccggctg	tcagcgagc	2100
ggcgcccggt	tctttttgtc	aagaccgacc	tgctcgggtg	cctgaatgaa	ctgcaggacg	2160
aggcagcgcg	gctatcgctg	ctggccacga	cgggcttcc	ttgcgcagct	gtgctcgacg	2220
ttgtcactga	agcgggaagg	gactggctgc	tattgggcga	agtgccgggg	caggatctcc	2280
tgctcatctca	ccttgctcct	gccgagaaa	tatccatcat	ggctgatgca	atgcggcggc	2340
tgcatagct	tgatccggct	acctgccc	tcgaccacca	agcgaacat	cgcattcgagc	2400
gagcagctac	tcggatggaa	gccggctctg	tcgatcagga	tgatctggac	gaagagcatc	2460
aggggctcgc	gccagccgaa	ctgttcgcca	ggctcaaggc	gcgcattgcc	gacggcgagg	2520
atctcgtcgt	gacccatggc	gatgcctgct	tgccgaatat	catggtggaa	aatggccgct	2580
tttctggatt	catcgactgt	ggcgggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	2640
tggtaccccg	tgatattgct	gaagagcttg	gcggcggaatg	ggctgaccgc	ttcctcgtgc	2700
tttacgggat	cgccgctccc	gattcgagc	gcctgcctt	ctatcgctt	cttgacgagt	2760
tcttctgagc	gggactctgg	ggttcgaaat	gaccgaccaa	gcgacgccc	acctgccatc	2820
acgagatttc	gattccaccg	ccgccttcta	tgaaagggtg	ggcttcggaa	tcgttttcg	2880
ggacgcccgc	tggatgatcc	tccagcgcg	ggatctcatg	ctggagtctt	tcgcccacgc	2940
tagcggcgcg	ccggccggcc	cggtgtgaaa	taccgcacag	atgcgtaagg	agaaaatacc	3000
gcatacggcg	ctcttcgct	tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	3060
ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	3120
acgcaggaaa	gaacatgtga	gcaaaaggcc	agcaaaaggc	caggaaccgt	aaaaaggccg	3180
cgttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatacacia	aatcgacgct	3240
caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	3300
gctccctcgt	gcgctctcct	gttcgcagcc	tgccgcttac	cggatacctg	tccgccttcc	3360
tcccttcggg	aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	agttcgggtg	3420
aggtcgctcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	3480
ccttatcccg	taactatcgt	cttgagtcca	acccggttaag	acacgactta	tcgcccactg	3540
cagcagccac	tggtaacagg	attagcagag	cgaggatgtg	aggcggtgct	acagagttct	3600
tgaagtgggtg	gcctaactac	ggctacacta	gaaggacagt	atcttggtatc	tgcgctctgc	3660
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	3720
ctggtagcgg	tgggtttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	3780
aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	aactcacgtt	3840
aagggatttt	ggtcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaaggccg	3900
gccgcggccg	ccatcggcct	tttcttttgc	gtttttatct	gttaactgtt	aattgtcctt	3960
gttcaaggat	gctgtctttg	acaacagatg	ttttcttgcc	tttgatgttc	agcaggaagc	4020
tcggcgcaaa	cgttgattgt	ttgtctgcgt	agaatcctct	gtttgtcata	tagcttgtaa	4080
tcacgacatt	gtttcctttc	gcttgaggta	cagcgaagtg	tgagtaagta	aaggttacat	4140
cgttaggata	aagatccatt	tttaacacaa	ggccagtttt	gttcagcggc	ttgtatgggc	4200
cagttaaaga	attagaaaca	taaccaagca	tgtaaatatc	gttagacgta	atgccgtcaa	4260
tcgtcatttt	tgatccgcgg	gagtcagtg	acaggtagca	tttgccgttc	attttaaga	4320
cgttcgcgcg	ttcaatttca	tctgttactg	tgtagatgc	aatcagcggt	ttcatcactt	4380
ttttcagtg	gtaatcatcg	tttagctcaa	tcataccgag	agcgccggtt	gctaactcag	4440
ccgtgcgttt	tttatcgctt	tgcagaagtt	tttgactttc	ttgacggaa	aatgatgtgc	4500
ttttgccata	gtatgctttg	ttaaataaag	attcttcgcc	ttggtagcca	tcttcagttc	4560
cagtgtttgc	ttcaaatact	aagtatttgt	ggcctttatc	ttctacgtag	tgaggatctc	4620
tcagcgtag	gttgctgcct	gagctgtagt	tgcttctatc	gatgaactgc	tgtacatttt	4680
gatacgtttt	tccgtcaccg	tcaaagattg	atttataatc	ctctacaccg	ttgatgttca	4740
aagagctgtc	tgatgctgat	acgttaactt	gtgcagttgt	cagtgtttgt	ttgccgtaat	4800
gtttaccgga	gaaatcagtg	tagaataaac	ggatttttcc	gtcagatgta	aatgtggctg	4860
aacctgacca	ttcttggtgt	tggtctttta	ggatagaatc	atctgcacgc	aattgtgcgc	4920
tgtctttaaa	gacgcggcca	gcgtttttcc	agctgtcaat	agaagtctcg	ccgacttttt	4980
gatagaacat	gtaaatcgat	gtgtcatccg	catttttagg	atctccgggt	aatgcaaa	5040

```

cgatgtggta gccgtgatag tttgcgacag tgccgtcagc gttttgtaat ggccagctgt 5100
cccaaacgtc caggcctttt gcagaagaga tatttttaaat tgtggacgaa tcaaattcag 5160
aaacttgata tttttcattt ttttgctgtt cagggatttg cagcatatca tggcgtgtaa 5220
tatgggaaat gccgtatgtt tccttatatg gcttttggtt cgtttctttc gcaaacgctt 5280
gagttgcgcc tcctgccagc agtgcggtag taaagggttaa tactgttgct tgttttgcaa 5340
actttttgat gttcatcggt catgtctcct tttttatgta ctgtgttagc ggtctgcttc 5400
ttccagccct cctgtttgaa gatggcaagt tagttacgca caataaaaaa agacctaaaa 5460
tatgtaaggg gtgacgcaa agtatacact ttgcccttta cacattttag gtcttgcttg 5520
ctttatcagt aacaaacccg cgcgatttac ttttcgacct cattctatta gactctcggt 5580
tggtattgcaa ctggtctatt ttctcttttt gtttgataga aaatcataaa aggtattgca 5640
gactacgggc ctaaagaact aaaaaatcta tctgtttctt ttcattctct gtatttttta 5700
tagtttctgt tgcatgggca taaagttgcc tttttaatca caattcagaa aatatcataa 5760
tatctcattt cactaaataa tagtgaacgg caggtatatg tgatgggtta aaaaggatcg 5820
gcggccgctc gatttaaate tcgagaggcc tgacgtcggg 5860

```

<210> 7

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 7

cggcaccacc gacatcatct tcacctgccc tcgttccg

38

<210> 8

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 8

cggaacgagg gcaggtgaag atgatgtcgg tgggtgccg

38

<210> 9

<211> 1263

<212> DNA

<213> Corynebacterium glutamicum

<400> 9

```

gtggccctgg tcgtacagaa atatggcggg tcctcgcttg agagtgcgga acgcattaga 60
aacgtcgctg aacggatcgt tgccaccaag aaggctggaa atgatgtcgt ggttgtctgc 120
tccgcaatgg gagacaccac ggatgaactt ctagaacttg cagcggcagt gaatcccgtt 180
ccgccagctc gtgaaatgga tatgtctctg actgctgggt agcgtatttc taacgtcttc 240
gtcgccatgg ctattgagtc ccttggcgca gaagcccaat ctttcacggg ctctcagggt 300
ggtgtgctca ccaccgagcg ccacggaaac gcacgcattg ttgatgtcac tccagggtcgt 360
gtgctgtaag cactcgatga gggcaagatc tgcattgttg ctggtttcca ggggtgtaat 420
aaagaaaccc gcgatgtcac cacgttgggt cgtggtgggt ctgacaccac tgcagttgctg 480
ttggcagctg ctttgaacgc tgatgtgtgt gagatttact cggacgttga cgggtgtgat 540
accgctgacc cgcgcacgtt tcctaattgca cagaagctgg aaaagctcag cttcgaagaa 600
atgctggaac ttgctgctgt tggctccaag attttgggtc tgcgagctgt tgaatacgtc 660
cgtgcattca atgtgccact tcgcgtacgc tegtcttata gtaatgatcc cggcactttg 720
attgccggtt ctatggagga tattcctgtg gaagaagcag tccttaccgg tgtcgcaacc 780
gacaagtccg aagccaaagt aaccgttctg ggtatttccg ataagccagg cgaggctgcg 840
aaggttttcc gtgogttggc tgatgcagaa atcaacattg acatggttct gcagaacgtc 900
tcttctgtag aagacggcac caccgacatc accttcacct gccctcgttc cgacggccgc 960

```

cgcgcgatgg	agatcttgaa	gaagcttcag	gttcagggca	actggacca	tgtgctttac	1020
gacgaccagg	tcggaaggt	ctccctcgtg	gggtgctggca	tgaagtctca	cccaggtggt	1080
accgcagagt	tcatggaagc	tctgcgcgat	gtcaacgtga	acatcgaatt	gatttccacc	1140
tctgagattc	gtatttccgt	gctgatccgt	gaagatgatc	tggatgctgc	tgcacgtgca	1200
ttgcatgagc	agttccagct	gggcggcgaa	gacgaagccg	tcgtttatgc	aggcaccgga	1260
cgc						1263

<210> 10

<211> 5860

<212> DNA

<213> Corynebacterium glutamicum

<400> 10

cccggtagca	cgcggtccag	tggtgagac	gcattccgcta	aagccccagg	aaccctgtgc	60
agaaagaaaa	cactcctctg	gctaggtaga	cacagtttat	aaaggtagag	ttgagcgggt	120
aactgtcagc	acgtagatcg	aaaggtgcac	aaaggtggcc	ctggctctac	agaaatatgg	180
cggttcctcg	cttgagagtg	cggaacgcac	tagaaacgtc	gctgaacgga	tcgttgccac	240
caagaaggct	ggaaatgatg	tcgtgggtgt	ctgctccgca	atgggagaca	ccacggatga	300
acttctagaa	cttgacagcg	cagtgaatcc	cgttccgcca	gctcgtgaaa	tggatatgct	360
cctgactgct	ggtagagcgt	tttctaaccg	tctcgtcgcc	atggctattg	agtcccttgg	420
cgcagaagcc	caatctttca	cgggctctca	ggctgggtgt	ctcaccaccg	agcgccaccg	480
aaacgcacgc	attgttgatg	tcactccagg	tcgtgtgctg	gaagcactcg	atgagggcaa	540
gatctgcatt	ggtgctgggt	tcagggtgtg	taataaagaa	acccgcgatg	tcaccacgtt	600
gggtcgtggg	ggttctgaca	ccactgcagt	tgctgtggca	gctgctttga	acgctgatgt	660
gtgtgagatt	tactcggacg	ttgacgggtg	gtataccgct	gacccgcgca	tcgttccctaa	720
tgcacagaag	ctggaaaagc	tcagcttcga	agaaatgctg	gaacttgctg	ctggtggctc	780
caagattttg	gtgctgcgca	gtgttgaata	cgctcgtgca	ttcaatgtgc	cacttcgcgt	840
acgctcgtct	tatagtaatg	atcccggcac	tttgattgcc	ggctctatgg	aggatatattc	900
tgtggaagaa	gcagtcctta	cgggtgtcgc	aaccgacaag	tccgaagcca	aagtaaccgt	960
tctgggtatt	tccgataagc	caggcgaggc	tgccaagggt	ttccgtgctg	tggctgatgc	1020
agaaatcaac	attgacattg	ttctgcagaa	cgtctcttct	gtagaagacg	gcaccaccga	1080
catcatcttc	acctgccctc	gttccgacgg	cgcctcgctg	atggagatct	tgaagaagct	1140
tcagggttcag	ggcaactgga	ccaatgtgct	ttacgacgac	caggctcgga	aagtctccct	1200
cgtgggtgct	ggcatgaagt	ctcaccacag	tggtaccgca	gagttcatgg	aagctctcgc	1260
cgatgtcaac	gtgaacatcg	aattgatttc	cacctctgag	attcgtatct	ccgtgctgat	1320
ccgtgaagat	gatctggatg	ctgctgcacg	tgcatatgat	gagcagttcc	agctgggctg	1380
cgaagacgaa	gccgtcgttt	atgcaggcac	cggacgctaa	agttttaaag	gagtagtttt	1440
acaatgacca	ccatcgcagt	tggttggtgca	accggccagg	tcggccagggt	tatgcgcacc	1500
cttttggaag	agcgcaattt	cccagctgac	actgttcggt	tctttgcttc	cccacgttcc	1560
gcaggccgta	agattgaatt	cgtcgacatc	gatgctcttc	tgctgtaatt	aacaattggg	1620
atcctctaga	cccgggattt	aaatcgctag	cgggctgcta	aaggaagcgg	aacacgtaga	1680
aagccagtcc	gcagaaacgg	tgctgacccc	ggatgaatgt	cagctactgg	gctatctgga	1740
caagggaaaa	cgcaagcgca	aagagaaagc	aggtagcttg	cagtgggctt	acatggcgat	1800
agctagactg	ggcgggttta	tggacagcaa	gcgaaccgga	attgccagct	ggggcgccct	1860
ctggtaagggt	tgggaagccc	tgcaaagtaa	actggatggc	tttcttgccg	ccaaggatct	1920
gatggcgtag	gggatcaaga	tctgatcaag	agacaggatg	aggatcgttt	cgcattgattg	1980
aacaagatgg	attgcacgca	ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	2040
actgggcaca	acagacaatc	ggctgctctg	atgccgcctg	gttccggctg	tcagcgtagg	2100
ggcgcccggt	tctttttgtc	aagaccgacc	tgtccgggtg	cctgaatgaa	ctgcaggacg	2160
aggcagcgcg	gctatcgtgg	ctggccacga	cgggcgttcc	ttgcgcagct	gtgctcgacg	2220
ttgtcactga	agcgggaagg	gactggctgc	tattgggcca	agtgcggggg	caggatctcc	2280
tgtcatctca	ccttgctcct	gccgagaaag	tatccatcat	ggctgatgca	atgcggcggc	2340
tgcatacgct	tgatccggct	acctgcccac	tcgaccacca	agcgaaacat	cgcattcgagc	2400
gagcacgtac	tcggatggaa	gccgggtctt	tcgatcagga	tgatctggac	gaagagcatc	2460
aggggctcgc	gccagccgaa	ctgttcgcca	ggctcaaggc	gcgcatgccc	gacggcgagg	2520
atctcgtcgt	gacccatggc	gatgcctgct	tgccgaatat	catgggtgaa	aatggccgct	2580
tttctggatt	catcgactgt	ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	2640
tggctaccgg	tgatattgct	gaagagcttg	gcggcgaaat	ggctgaccgc	ttcctcgtgc	2700
tttacggtat	gcacgctccc	gattcgcagg	gcattcgcct	ctatcgcctt	cttgacgagt	2760
tcttctgagc	gggactctgg	ggttcgaaat	gaccgaccaa	gcgacgcccc	acctgccatc	2820
acgagatttc	gattccaccg	ccgccttcta	tgaaggtgtg	ggcttcggaa	tcgttttccg	2880

BGI-159PC

```

ggacgccggc tggatgatcc tccagcgccg ggatctcatg ctggagttct tgcgccacgc 2940
tagcgccgcg ccggccggcc cgggtgtgaaa taccgcacag atgcgtaagg agaaaatacc 3000
gcatcaggcg ctcttccgct tccctcgctca ctgactcgct gcgctcggtc gttcggctgc 3060
ggcgagcggc atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata 3120
acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 3180
cggttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct 3240
caagtcagag gtggcgaaac ccgacaggac tgccgcttac cggatacctg tccgcctttc 3300
gctccctcgt gcgctctcct gttccgaccc tgcgcttac cggatacctg tccgcctttc 3360
tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcgggtg 3420
aggctcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg 3480
ccttatccgg taactatcgt cttgagtcca acccggttaag acacgactta tgcgactgg 3540
cagcagccac tggtaacagg attagcagag cgaggtatgt aggcgggtgct acagagttct 3600
tgaagtgggt gcctaactac ggctacacta gaaggacagt atttgggtatc tgcgctctgc 3660
tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg 3720
ctggtagcgg tgggtttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc 3780
aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgct 3840
aagggtattt ggtcatgaga ttatcaaaaa ggactctcac ctagatcctt ttaaaggccg 3900
gccgcccggc ccatcgccat tttcttttgc gtttttattt gttaactgtt aattgtcctt 3960
gttcaaggat gctgtctttg acaacagatg ttttcttgcc tttgatgttc agcaggaagc 4020
tcggcgcaaa cgttgattgt ttgtctgcgt agaatcctct gtttgtcata tagcttgtaa 4080
tcacgacatt gtttcctttc gcttgaggta cagcgaagtg tgagtaagta aaggttacat 4140
cgttaggatc aagatccatt ttaacacaaa ggccagtttt gttcagcggc ttgtatgggc 4200
cagttaaaga attagaaaca taaccaagca tgtaaatac gttagacgta atgcccgtca 4260
tcgtcatttt tgatccgcgg gagtcagtga acaggtacca tttgccgttc attttaaaga 4320
cgttccgcgg tccaatttca tctgttactg tgttagatgc aatcagcggg ttcacactt 4380
ttttcagtg gtaatcatcg tttagctcaa tcataccgag agcgcgggtt gctaactcag 4440
ccgtgcgttt tttatcgctt tgcagaagtt tttgactttc ttgacggaag aatgatgtgc 4500
ttttgccata gtatgctttg ttaaataaag attcttcgcc ttggtagcca tcttcagttc 4560
cagtgtttgc ttcaaatact aagtatttgt ggcctttatc ttctacgtag tgaggatctc 4620
tcagcgtatg gttgtcgctt gagctgtagt tgccttcac gatgaactgc tgtacatttt 4680
gatacgtttt tccgtcaccc tcaaagattg atttataatc ctctacaccg ttgatgttca 4740
aagagctgtc tgatgctgat acgttaactt gtgcagttgt cagtgtttgt ttgccgtaat 4800
gtttaccgga gaaatcagtg tagaataaac ggatttttcc gtcagatgta aatgtggctg 4860
aacctgacca ttcttggtt tggcttttta ggatagaatc atttgcatcg aatttgctcg 4920
tgtctttaaa gacgcggcca gcgtttttcc agctgtcaat agaagtttcg ccgacttttt 4980
gatagaacat gtaaatcgat gtgtcatccg catttttagg atctccggct aatgcaaaga 5040
cgatgtggta gccgtgatag tttgcgacag tgccgtcagc gttttgtaat ggccagctgt 5100
cccaaacgtc caggcctttt gcagaagaga tatttttaat tgtggacgaa tcaaattcag 5160
aaacttgata ttttccattt ttttgctggt cagggatttg cagcatatca tggcgtgtaa 5220
tatgggaaat gccgtatgtt tccttatatg gcttttgggt cgtttctttc gcaaaccgctt 5280
gagttgcgcc tccgtccagc agtgcggtag taaagggtta tactgttgct tgttttgcaa 5340
actttttgat gttcatcggt catgtctcct tttttatgta ctgtgttagc ggtctgcttc 5400
ttccagccct cctgtttgaa gatggcaagt tagttacgca caataaaaaa agacctaaaa 5460
tatgtaaggg gtgacgcca agtatacact ttgcccctta cacattttag gtcttgcttg 5520
ctttatcagt aacaaacccg cgcgatttac ttttcgacct cattctatta gactctcgct 5580
tggattgcaa ctggtctatt ttcctctttt gtttgataga aaatcataaa aggatttgca 5640
gactacgggc ctaaagaact aaaaaatcta tctgtttctt ttcattctct gtatttttta 5700
tagtttctgt tgcattggca taaagttgcc tttttaatca caattcagaa aatatcataa 5760
tatctcattt cactaaataa tagtgaacgg caggtatatg tgatgggtta aaaaggatcg 5820
gcggccgctc gatttaaatc tcgagaggcc tgacgtcggg 5860

```

<210> 11

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 11

ggccgctagc gtttttggtc accccggaat

30

<210> 12

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 12

ggcctctaga acacgcttgg accagtgtt

30

<210> 13

<211> 5720

<212> DNA

<213> Corynebacterium glutamicum

<400> 13

```

ggctcgactct agaggatccc cgggtaccga gctcgaattc actggccgctc gttttacaac 60
gtcgtgactg ggaaaaccct ggcgttacct aacttaatcg ccttgacgca catccccctt 120
tcgccagctg gcgtaatagc gaagaggccc gcaccgatcg cccttcccaa cagttgcgca 180
gcctgaatgg cgaatggcga taagctagct tcacgctgcc gcaagcactc agggcgcaag 240
ggctgctaaa ggaagcggaa cacgtagaaa gccagtcgca agaaacgggtg ctgacccccg 300
atgaatgtca gctactgggc tatctggaca agggaaaacg caagcgcaaa gagaaagcag 360
gtagcttgca gtgggcttac atggcgatag ctagactggg cggttttatg gacagcaagc 420
gaaccggaat tgccagctgg ggcgccctct ggtaagggtg ggaagccctg caaagtaaag 480
tggtatggctt tcttgccgcc aaggatctga tggcgaggg gatcaagatc tgatcaagag 540
acaggatgag gatcgctttcg catgattgaa caagatggat tgcacgcagg ttctccggcc 600
gcttgggtgg agaggctatt cggctatgac tgggcacaac agacaatcgg ctgctctgat 660
gccgccgtgt tccggctgtc agcgagggg cgcccggttc tttttgtcaa gaccgacctg 720
tccggtgccc tgaatgaact ccaagacgag gcagcgcgcc tatcgtggct ggccacgacg 780
ggcgttcctt gcgcagctgt gctcgacgtt gtcactgaag cgggaaggga ctggctgcta 840
ttgggcgaag tgccggggca ggatctcctg tcatctcacc ttgctcctgc cgagaaagta 900
tccatcatgg ctgatgcaat gcggcggtcg catacgcttg atccggctac ctgcccattc 960
gaccaccaag cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggctctgtc 1020
gatcaggatg atctggacga agagcatcag ggcctcgcgc cagccgaact gttcgccagg 1080
ctcaaggcgc ggatgcccga cggcgaggat ctcgtcgtga eccatggcga tgccctgttg 1140
ccgaatatca tgggtgaaaa tggccgcttt tctggattca tgcactgtgg ccggctgggt 1200
gtggcggacc gctatcagga catagcgttg gctaccctg atattgctga agagcttggc 1260
ggcgaatggg ctgaccgctt cctcgtgctt tacggtatcg ccgctcccga ttgcgagcgc 1320
atcgcccttct atcgcccttct tgacgagttc ttctgagcgg gactctgggg ttcgctagag 1380
gatcgatcct ttttaaccca tcacatatac ctgccgttca ctattattta gtgaaatgag 1440
atattatgat attttctgaa ttgtgattaa aaaggcaact ttatgcccat gcaacagaaa 1500
ctataaaaaa tacagagaat gaaaagaaac agatagattt tttagttctt tagggccgta 1560
gtctgcaaat ctttttatga ttttctatca aacaaaagag gaaaatagac cagttgcaat 1620
ccaaacgaga gtctaataga atgaggtcga aaagtaaate gcgcgggttt gttactgata 1680
aagcaggcaa gacctaaaat gtgtaaaggg caaagtgtat actttggcgt cacccttac 1740
atatttttag tcttttttta ttgtgcgtaa ctaacttgcc atcttcaaac aggagggtg 1800
gaagaagcag accgctaaca cagtacataa aaaaggagac atgaacgatg aacatcaaaa 1860
agtttgcaaa acaagcaaca gtattaacct ttactaccgc actgctggca ggaggcgcaa 1920
ctcaagcgtt tgcgaaagaa acgaaccaa agccatataa ggaaacatac ggcatctccc 1980
atattacacg ccatgatatg ctgcaaatcc ctgaacagca aaaaaatgaa aaatatcaag 2040
tttctgaatt tgattcgtcc acaattaaaa atatctcttc tgcaaaaggc ctggacgttt 2100
gggacagctg gccattacaa aacgctgacg gcactgtcgc aaactatcac ggctaccaca 2160
tcgtctttgc attagccgga gatcctaata atgcggatga cacatcgatt tacatgttct 2220
atcaaaaagt cggcgaaact tctattgaca gctggaaaaa cgctggccgc gtcttttaaag 2280

```

acagcgacaa	attcgatgca	aatgattcta	tcctaaaaga	ccaaacacaa	gaatgggtcag	2340
gttcagccac	atttacatct	gacggaaaaa	tccgttttatt	ctacactgat	ttctccggta	2400
aacattacgg	caaacaaaca	ctgacaactg	cacaagttaa	cgtatcagca	tcagacagct	2460
ctttgaacat	caacgggtgta	gaggattata	aatcaatctt	tgacgggtgac	ggaaaaacgt	2520
atcaaaatgt	acagcagttc	atcgatgaag	gcaactacag	ctcaggcgac	aaccatacgc	2580
tgagagatcc	tcactacgta	gaagataaag	gccacaaata	cttagtattt	gaagcaaaaca	2640
ctggaactga	agatggctac	caaggcgaag	aatcttttatt	taacaaagca	tactatggca	2700
aaagcacatc	attcttccgt	caagaaaagtc	aaaaacttct	gcaaagcgat	aaaaaacgca	2760
cggctgagtt	agcaaacggc	gctctcggta	tgattgagct	aaacgatgat	tacacactga	2820
aaaaagtgat	gaaaccgctg	attgcatcta	acacagtaac	agatgaaatt	gaacgcgcga	2880
acgtctttta	aatgaacggc	aaatgggtacc	tgttcactga	ctcccgcgga	tcaaaaatga	2940
cgattgacgg	cattacgtct	aacgatattt	acatgcttgg	ttatgtttct	aattctttta	3000
ctggcccata	caagccgctg	aacaaaactg	gccttggtgt	aaaaatggat	cttgatccta	3060
acgatgtaac	ctttactttac	tcacacttcg	ctgtacctca	agcgaaagga	aacaatgtcg	3120
tgattacaag	ctatatgaca	aacagaggat	tctacgcaga	caaacaatca	acgttttgcgc	3180
cgagcttctt	gctgaacatc	aaaggcaaga	aaacatctgt	tgtcaaagac	agcatccttg	3240
aacaaggaca	attaacagtt	aacaaataaa	aacgcaaaag	aaaatgccga	tgggtaccga	3300
gcgaaatgac	cgaccaagcg	acgccccacc	tgccatcacg	agatttctgat	tccaccgcgcg	3360
ccttctatga	aagggttgggc	ttcggaatcg	ttttccggga	cgccctcgcg	gacgtgctca	3420
tagtccacga	cgcccggtgat	tttgtagccc	tgcccgacgg	ccagcaggta	ggccgacagg	3480
ctcatgcggg	ccgcgcgcgc	cttttccctca	atcgctcttc	gttcgtctgg	aaggcagtag	3540
accttgatag	gtgggctgcc	cttccctggt	ggcttggttt	catcagccat	ccgcttgccc	3600
tcatctgtta	cgccggcggg	agccggccag	cctcgcagag	caggattccc	gttgagcacc	3660
gccaggtgcg	aataagggac	agtgaagaag	gaacacccgc	tcgcgggtgg	gcctacttca	3720
cctatcctgc	ccggttgacg	ccgttgataa	caccaaggaa	agtctacacg	aacccttttg	3780
caaatccctg	tatatctgtc	gaaaaaggat	ggatataacc	aaaaaatcgc	tataatgacc	3840
ccgaagcagg	gttatgcagc	ggaaaagcgc	tgcttccctg	ctgttttgtg	gaatatctac	3900
cgactggaaa	caggcaaattg	caggaaatta	ctgaactgag	gggacaggcg	agagacgatg	3960
ccaaagagct	cctgaaaatc	tcgataactc	aaaaaatacg	cccggtagtg	atcttatttc	4020
attatggtga	aagtgtggaac	ctcttacgtg	ccgatcaacg	tctcattttc	gccaaaagtt	4080
ggcccagggc	ttcccgggtat	caacagggac	accaggattt	atttattctg	cgaagtgatc	4140
ttccgtcaca	ggtattttatt	cggcgcaaaag	tgcgctcgggt	gatgctgcca	acttactgat	4200
ttagtgtatg	atggtgtttt	tgaggtgctc	cagtggtctc	tgtttctatc	agctcctgaa	4260
aatctcgata	actcaaaaaa	tacgcccgtt	agtgactctta	tttcattatg	gtgaaagttg	4320
gaacctctta	cgtgccgatac	aacgtctcat	tttcgccaaa	agttggccca	gggcttcccg	4380
gtatcaacag	ggacaccagg	atttattttat	tctgcgaagt	gatcttccgt	cacagggtatt	4440
tattcggcgc	aaagtgcgtc	gggtgatgct	gccaaacttac	tgatttagtg	tatgatggtg	4500
tttttgaggt	gctccagtgg	cttctgtttc	tatcagggct	ggatgatcct	ccagcgcggg	4560
gatctcatgc	tggagttctt	cgcccacccc	aaaaggatct	aggtgaagat	cctttttgat	4620
aatctcatga	ccaaaatccc	ttaacgtgag	ttttcgttcc	actgagcgtc	agacccccta	4680
gaaaagatca	aaggatcttc	ttgagatcct	ttttttctgc	gcgtaatctg	ctgcttgcaa	4740
acaaaaaaac	caccgctacc	agcgggtggt	tgtttgccgg	atcaagagct	accaactctt	4800
tttccgaagg	taactggctt	cagcagagcg	cagataccaa	atactgttct	tctagtgtag	4860
ccgtagttag	gccaccactt	caagaactct	gtagcaccgc	ctacatacct	cgtctgcta	4920
atcctgttac	cagtggctgc	tgccagtggc	gataagtcgt	gtcttaccgg	gttggaactca	4980
agacgatagt	taccggataa	ggcgcagcgg	tcgggctgaa	cggggggttc	gtgcacacag	5040
cccagcttgg	agcgaacgac	ctacaccgaa	ctgagatacc	tacagcgtga	gctatgagaa	5100
agcgccacgc	ttcccgaagg	gagaaaggcg	gacagggtatc	cggtaaagcg	cagggtcgga	5160
acaggagagc	gcacgagggg	gcttccaggg	ggaaacgcct	ggtatcttta	tagtcctgtc	5220
gggtttcgcc	acctctgact	tgagcgtcga	ttttgtgat	gctcgtcagg	ggggcgaggc	5280
ctatggaaaa	acgccagcaa	cgcggccttt	ttacggttcc	tggccttttg	ctggcctttt	5340
gctcacatgt	tctttcctgc	gttatccctt	gattctgtgg	ataaccgtat	taccgccttt	5400
gagtgaatgc	ataccgctcg	ccgcagccga	acgaccgagc	gcagcagatc	agtgagcgag	5460
gaagcggaag	agcgcctaat	acgcaaaccg	cctctccccg	cgcgttggcc	gattcattaa	5520
tgcagctggc	acgacaggtt	tcccgaactg	aaagcgggca	gtgagcgcaa	cgcaattaat	5580
gtgagttagc	tcactcatta	ggcaccctag	gctttacact	ttatgcttcc	ggctcgtagt	5640
ttgtgtggaa	ttgtgagcgg	ataacaattt	cacacaggaa	acagctatga	ccatgattac	5700
gccaagcttg	catgcctgca					5720

<210> 14
 <211> 6680
 <212> DNA
 <213> Corynebacterium glutamicum

<400> 14
 ggtcgactct agaacacgct tggaccagtg cttggcgctg ccactggtgg cgaaaccacc 60
 gtgaagtaca ccagcgacca gaactctgag gttactttcg tgccgtttga aaatggcatc 120
 atggtgtctt cccctgaggc tggaaactcac ggctgtggg gcgcaatcgg tgacgcgtgg 180
 gctcagcagg gcgctgacct tggccctctg ggacttccaa ccagtaatga ataccctgt 240
 ggcgaacagc ttcgtgttga tttccagaat ggttacatca cttacgattc tgcgactggc 300
 caggcaagca ttcagctgaa ctagtctcaa ttagagccga aaaccccgct acctccctg 360
 aggaggcggg gttttctcca atcaaaagcc aattaaaggc cgacccaaat cagctaggcc 420
 tggtcataag aatgctccac tgccctattc cattcggcat agcgacgttc gcgctcttct 480
 tcgctcatgt cagggttcca gactttcttc actgcaataa gtttttcgat ctcgtcagtt 540
 gttttgaaga atccagagcc gagacctgca gcgaatgcga cgccgacggc ggtggtttct 600
 acgtcctcga gacgttggac gtcgatgccg aggaagtccg cttgcatttg catgaggagg 660
 tcattttcca ccatcgaccc gtcgacgcgg agggattcga gggctttgcc tgcgtctttg 720
 gccatggcgt ccacaacttc gcgggttttg aaggcgttgg cttcaaggac tgcgcgggcg 780
 atgtgtttgc gggtggcaaa acgggtgagg cctgtaataa cgccacgagc atcggggcgc 840
 caacgtgggtg cgaacagtcc ggtgaatgct gggacaacat gaacgccacc gttgtcttcg 900
 acttctcggg cgaggttttc aatcgctggg gcgttgggga ttagctgtag gttgtcgcgc 960
 agccactgca ccaaggaacc gccatggat acggaacctt ccagcgcgta gaccggagcg 1020
 gatccttccc gttgataggc gatggtggac agcaggccgt gctcggaaat cttcaacgag 1080
 gtcccggtgt tcatcagcag gaagaggccg gtgcegtagg tatttttagc agcaccttcg 1140
 tggaaatccg cctgaccaaa aacgctagct tcacgctgcc gcaagcactc agggcgcaag 1200
 ggctgctaaa ggaagcggaa cacgtagaaa gccagtccgc agaaacggtg ctgaccccg 1260
 atgaatgtca gctactgggc tatctggaca agggaaaacg caagcgcaaa gagaaagcag 1320
 gtagcttgca gtgggcttac atggcgatag ctgactggg cggttttatg gacagcaagc 1380
 gaaccggaat tgccagctgg ggccctctt ggtaagggtg ggaagccctg caaagtaaac 1440
 tggatggctt tcttgccgcc aaggatctga tggcgaggg gatcaagatc tgatcaagag 1500
 acaggatgag gatcgtttcg catgattgaa caagatggat tgcacgcagg ttctccggcc 1560
 gcttgggtgg agaggctatt cggctatgac tgggcacaac agacaatcgg ctgctctgat 1620
 gcccgctgtg tccggctgtc agcgagggg cgcccggttc tttttgtcaa gaccgacctg 1680
 tccggtgccc tgaatgaact ccaagacgag gcagcgcggc tatcgtggct ggccacgacg 1740
 ggcgttcctt gcgcagctgt gctcgacgtt gtcactgaag cggaaggga ctggctgcta 1800
 ttgggcgaag tgccggggca ggatctcctg tcatctcacc ttgctcctgc cgagaaagta 1860
 tccatcatgg ctgatgcaat gcggcggtg catagcgttg atccggctac ctgcccattc 1920
 gaccaccaag cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggctctgtc 1980
 gatcaggatg atctggacga agagcatcag gggctcgcgc cagccgaact gttcgccagg 2040
 ctcaaggcgc ggatgcccga cggcgaggat ctcgctgta cccatggcga tgectgtttg 2100
 ccgaatatca tgggtgaaaa tgcccgcttt tctggattca tcgactgtgg ccggctgggt 2160
 ctggcgagcc gctatcagga catagcgttg gctacccgtg atattgtgta agagcttggc 2220
 ggcgaaatggg ctgaccgctt cctcgtgctt tacggtatcg ccgctcccgga ttgcgagcgc 2280
 atcgcttctt atcgcttctt tgacgagttc ttctgagcgg gactctgggg ttctgtagag 2340
 gatcgatcct ttttaaccca tcacatatat ctgccgttca ctattattta gtgaaatgag 2400
 atattatgat attttctgaa ttgtgattaa aaaggcaact ttatgcccatt gcaacagaaa 2460
 ctataaaaaa tacagagaat gaaaagaaac agatagattt tttagtctt taggcccgta 2520
 gtctgcaaat ctttttatga ttttctatca aacaaaagag gaaaatagac cagttgcaat 2580
 ccaaacgaga gtctaataga atgaggtcga aaagtaaatc gcgcgggttt gttactgata 2640
 aagcaggcaa gacctaataa gtgtaaaggg caaagtgtat actttggcgt cacccttac 2700
 atatttttag tcttttttta ttgtgcgtaa ctaacttgcc atcttcaaac aggagggtcg 2760
 gaagaagcag accgctaaca cagtacataa aaaaggagac atgaacgatg aacatcaaaa 2820
 agtttgcaaa acaagcaaca gtattaacct ttactaccgc actgctggca ggaggcgcaa 2880
 ctcaagcgtt tgcgaaagaa acgaaccaa agccatataa ggaaacatac ggcatttccc 2940
 atattacacg ccatgatatg ctgcaaatcc ctgaacagca aaaaaatgaa aaatatcaag 3000
 tttctgaatt tgattcgtcc acaattaaaa atatctcttc tgcaaaaggc ctggacgttt 3060
 gggacagctg gccattacaa aacgctgacg gcactgtcgc aaactatcac ggctaccaca 3120
 tcgtctttgc attagccgga gatcctaaaa atgcggaatga cacatcgatt tacatgttct 3180
 atcaaaaagt cggcgaaact tctattgaca gctggaaaaa cgctggccgc gtcttttaag 3240
 acagcgacaa attcgtatga aatgattcta tcctaaaaga ccaaacacaa gaatggtcag 3300

```

gttcagccac atttacatct gacggaaaaa tccggtttatt ctacactgat ttctccggta 3360
aacattacgg caaacaaca ctgacaactg cacaaggttaa cgtatcagca tcagacagct 3420
ctttgaacat caacggtgta gaggattata aatcaatctt tgacggtgac ggaaaaacgt 3480
atcaaaatgt acagcagttc atcgatgaag gcaactacag ctcaggcgac aaccatacgc 3540
tgagagatcc tcactacgta gaagataaag gccacaaata cttagtattt gaagcaaca 3600
ctggaactga agatggctac caaggcgaag aatctttatt taacaaagca tactatggca 3660
aaagcacatc attcttccgt caagaaagtc aaaaacttct gcaaagcgat aaaaaacgca 3720
cggctgagtt agcaaacggc gctctcggta tgattgagct aaacgatgat tacacactga 3780
aaaaagtgat gaaaccgctg attgcatcta acacagtaac agatgaaatt gaacgcgcga 3840
acgtctttaa aatgaacggc aaatggtacc tggttcactga ctcccgcgga tcaaaaatga 3900
cgattgacgg cattacgtct aacgatattt acatgcttgg ttatgtttct aattctttaa 3960
ctggcccata caagccgctg aacaaaactg gccttgtgtt aaaaatggat cttgatccta 4020
acgatgtaac ctttacttac tcacacttcg ctgtacctca agcgaaagga aacaatgtcg 4080
tgattacaag ctatatgaca aacagaggat tctacgcaga caaacaatca acgtttgcgc 4140
cgagcttctc gctgaacatc aaaggaaga aacatctgt tgtcaaagac agcatccttg 4200
aacaaggaca attaacagtt aacaaataaa aacgcaaaag aaaatgccga tgggtaccga 4260
gcgaaatgac cgaccaagcg acgcccaccc tgccatcacg agatttcgat tccaccgcgc 4320
ccttctatga aaggttgggc ttcggaatcg ttttccggga cgccctcgcg gacgtgctca 4380
tagtccacga cgcccgctgat tttgtagccc tggccgacgg ccagcaggta ggccgacagg 4440
ctcatgccgg ccgcccgcgc cttttcctca atcgctcttc gtctgtctgg catcagccat ccgcttgcgc 4500
accttgatag gtgggctgcc cttcctggtt ggcttggttt cctcgtagag caggattccc gttgagcacc 4560
tcactgttta cgccggcggt agcgggccag cctcgtagag cagcaccgc tcgcgggtgg gcctacttca 4620
gccaggtgcg aataagggac agtgaagaag gaacaccgc caccaaggaa agtctacacg aacccttgg 4680
cctatcctgc ccggtgacg ccgttggata gaaaaaggat ggatataccg aaaaaatcgc tataatgacc 4740
caaaatcctg tatatcgtgc gaaaaaggat ggaaaaagcg tgcttccctg ctgttttctg gaatatctac 4800
ccgaagcagg gttatgcagc ggaaaaagcg ctgaactgag gggacaggcg agagacgatg 4860
cgactggaaa caggcaaatt caggaatta tgcataactc aaaaaatacg cccggtagtg atcttatttc 4920
ccaaagagct cctgaaaatc tgcataactc ctcttacgtg ccgatcaacg accaggattt atttattctg cgaagtgatc 4980
attatggtga aagttggaac ctcttacgtg accaggattt atttattctg gatgctgcca acttactgat 5040
ggcccagggc ttcccggat atcttaccgt cagcaccgc agtggcttc tttcgccaaa agttggccca gggcttcccg 5100
ttccgtcaca ggtatttatt cgccgcaaa agtggcttc tttcgccaaa agttggccca gggcttcccg 5160
ttagtgatg atggtgtttt tgaggtgctc agtggcttc tttcgccaaa agttggccca gggcttcccg 5220
aatctcgata actcaaaaaa aacgtctcat tctgcgaagt gccaacttac tgatttagtg tatgatggtg 5280
gaacctctta cgtgccgatc atcttaccgt tctgcgaagt gccaacttac tgatttagtg tatgatggtg 5340
gtatcaacag ggacaccagg atttatttat tctgcgaagt gccaacttac tgatttagtg tatgatggtg 5400
tattcggcgc aaagtgcgtc ggggtgatgct gccaacttac tgatttagtg tatgatggtg 5460
tttttgaggt gctccagtgg cttctgtttc tatcagggtt ggaatgaccc cctttttgat 5520
gatctcatgc tggagttctt cgccaccccc ttaacgtgag ttttcgttcc actgagcgtc agaccccgta 5580
aatctcatga ccaaaatccc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa 5640
gaaaagatca aaggatcttc agcgggtggt tgattgccc atcaagagct accaactctt 5700
acaaaaaac caccgctacc cagcagagcg cagataccaa atactgttct tctagtgtag 5760
tttccgaagg taactggctt caagaactct gtagcaccgc ctacatacct cgctctgcta 5820
ccgtagttag gccaccactt tgccagtggc gataagtcgt gtcttaccgg gttggactca 5880
atcctgttac cagtggctgc ggcgcagcgg tcgggctgaa cgggggggtt gtgcacacag 5940
agacgatagt taccggataa ggcgcagcgg ctgagatacc tacagcgtag gctatgagaa 6000
cccagcttgg agcgaacgac ctacaccgaa gacaggtatc cggtaagcgg ggtatcttta tagtctgtc 6060
agcgcacgc ttcccgaagg gcttccaggg ggaacgcct ggtatcttta tagtctgtc 6120
acaggagagc gcacgagggg tgagcgctga tttttgtgat gctcgtcagg gggcgaggc 6180
gggtttcgcc acctctgact tgagcgctga tttttgtgat gctcgtcagg gggcgaggc 6240
ctatgaaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg ctggcctttt 6300
gctcacatgt tctttcctgc gttatcccc tttctgtggt ataaccgtat taccgccttt 6360
gagttagctg ataccgctcg ccgcagccga acgaccgagc gcagcgagtc agtgagcgag 6420
gaagcggaag agcgcacca acgcaaaccg cctctcccc cgcggtggcc gattcattaa 6480
tgcagctggc acgacaggtt tcccgaactg aaagcgggca gtgagcgcaa cgcaattaat 6540
gtgagttagc tcaactatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg 6600
ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac 6660
gccaagcttg catgcctgca 6680

```

<210> 15
 <211> 6272
 <212> DNA
 <213> *Corynebacterium glutamicum*

<400> 15
 ggtcgactct agaacacgct tggaccagtg cttggcgctg ccactggtgg cgaaaccacc 60
 gtgaagtaca ccagcgacca gaactctgag gttactttcg tgccgtttga aaatggcatc 120
 atggtgtctt cccctgagggc tggaaactcac ggcctgtggg gcgcaatcgg tgacgcgtgg 180
 gctcagcagg gcgctgacct tggccctctg ggacttccaa ccagtaatga ataccacgtt 240
 ggcgaacagc ttcgtgttga tttccagaat ggttacatca cttacgattc tgcgactggc 300
 caggcaagca ttcagctgaa ctagtctcaa ttagagccga aaaccccgtc accttccctg 360
 aggaggcggg gttttctcca atcaaaagcc aattaaaggc cgacccaaat cagctaggcc 420
 tggtcataag aatgctccac tggcctattc cattcgcat agcgacgttc gcgctcttct 480
 tcgctcatgt cagggttcca gactttcttc actgcaataa gtttttcgat ctctgcagtt 540
 gttttgaaga atccagagcc gagacctgca gcgaatgcga cgccgacggc ggtggtttct 600
 acgtcctcga gggatccttc ccgttgatag gcgatggtgg acagcaggcc gtgctcggaa 660
 atcttcaacg aggtgccggt gttcatcagc aggaagaggc cggtgccgta ggtattttta 720
 gcagcacctt cgtggaatcc gccctgacca aaaacgctag cttcacgctg ccgcaagcac 780
 tcagggcgca agggctgcta aaggaagcgg aacacgtaga aagccagtcc gcagaaacgg 840
 tgctgacccc ggatgaatgt cagctactgg gctatctgga caagggaaaa cgcaagcgca 900
 aagagaaagc aggtagcttg cagtgggctt acatgcgcat agctagactg ggcggtttta 960
 tggacagcaa gcgaaccgga attgccagct ggggcgccct ctggttaagggt tgggaagccc 1020
 tgcaaaagtaa actggatggc tttcttgccg ccaaggatct gatggcgag gggatcaaga 1080
 tctgatcaag agacaggatg aggatcgttt cgcgatgttg aacaagatgg attgcacgca 1140
 gggttctccg ccgcttggtt ggagaggcta ttcggctatg actgggcaca acagacaatc 1200
 ggctgctctg atgccgccgt gttccggctg tcagcgcagg ggcgcccggt tctttttgtc 1260
 aagaccgacc tgtccggtgc cctgaatgaa ctccaagacg aggcagcgcg gctatcgtgg 1320
 ctggccacga cgggcgttcc ttgcccagct gtgctcgacg ttgtcactga agcgggaagg 1380
 gactggctgc tattgggcga agtgccgggg caggatctcc tgtcatctca ccttgctcct 1440
 gccgagaaag tatccatcat ggctgatgca atgcggcgcc tgcatacgct tgatccgggt 1500
 acctgcccac tcgaccacca agcgaacatc cgcctcgagc gagcacgtac tcggatggaa 1560
 gccggctctt tcgatcagga tgatctggac gaagagcatc aggggctcgc gccagccgaa 1620
 ctgttcgcca ggctcaaggc gcggatgccc gacggcgagg atctcgtcgt gaccatggc 1680
 gatgcctgct tgccgaatat catggtggaa aatggccgct tttctggatt catcgactgt 1740
 ggccggctgg gtgtggcgga ccgctatcag gacatagcgt tggctaccgg tgatattgct 1800
 gaagagcttg gcggcgaatg ggctgaccgc ttccctcgtgc tttacggtat cgccgctccc 1860
 gattcgcagc gcatcgccct ctatcgccct cttgacgagt tcttctgagc gggactctgg 1920
 gggtcgttag aggatcgatc ctttttaacc catcacatat acctgccgtt cactattatt 1980
 tagtgaatag agatattatg atattttctg aattgtgatt aaaaaggcaa ctttatgccc 2040
 atgcaacaga aactataaaa aatacagaga atgaaaagaa acagatagat tttttagttc 2100
 tttaggcccg tagtctgcaa atccttttat gattttctat caaacaagag aggaaaatag 2160
 accagttgca atccaaacga gagtctaata gaatgaggtc gaaaagtaaa tcgcgcgggg 2220
 ttgttactga taaagcaggc aagacctaaa atgtgtaaag ggcaaagtgt atactttggc 2280
 gtcacccctt acatatttta ggtctttttt tattgtgctg aactaacttg ccactctcaa 2340
 acaggagggc tggaagaagc agaccgctaa cacagtacat aaaaaaggag acatgaacga 2400
 tgaacatcaa aaagtttgca aaacaagcaa cagtattaac ctttactacc gcactgctgg 2460
 caggaggcgc aactcaagcg tttgcgaaag aaacgaacca aaagccatat aaggaacat 2520
 acggcatttc ccatattaca cgccatgata ccttgcaaat ccctgaacag caaaaaaatg 2580
 aaaaatatca agtttctgaa tttgattcgt ccacaattaa aaatatctct tctgcaaaag 2640
 gcctggacgt ttgggacagc tggccattac aaaacgctga cggcactgtc gcaaactatc 2700
 acggctacca catcgtcttt gcattagccg gagatcctaa aaatgcggat gacacatcga 2760
 tttacatgtt ctatcaaaaa gtcggcgaaa cttctattga cagctggaaa aacgctggcc 2820
 gcgtctttta agacagcgac aaattcgatg caaatgattc tatcctaaaa gaccaaacac 2880
 aagaatggtc aggttcagcc acattttacat ctgacggaaa aatccgttta ttctacactg 2940
 atttctccgg taaacattac ggcaaacaaa cactgacaac tgcacaagtt aacgtatcag 3000
 catcagacag ctctttgaac atcaacggtg tagaggatta taaatcaatc tttgacggtg 3060
 acggaaaaaa gtatcaaaat gtacagcagt tcactcgatg aggcaactac agctcaggcg 3120
 acaaccatac gctgagagat cctcactacg tagaagataa aggccacaaa tacttagtat 3180
 ttgaagcaaa cactggaact gaagatggct accaaggcga agaactctta ttttaacaaag 3240
 catactatgg caaaagcaca tcattcttcc gtcaagaaaag tcaaaaactt ctgcaaaagc 3300

ataaaaaaacg	cacggctgag	ttagcaaacg	gcgctctcgg	tatgattgag	ctaaacgatg	3360
attacacact	gaaaaaagt	atgaaaccgc	tgattgcac	taacacagta	acagatgaaa	3420
ttgaacgcgc	gaacgtcttt	aaaatgaacg	gcaaattggt	cctgttccact	gactcccgcg	3480
gatcaaaaat	gacgattgac	ggcattacgt	ctaacgat	ttacatgctt	ggttatgttt	3540
ctaattcttt	aactggccca	tacaagccgc	tgaacaaaac	tgcccttggt	ttaaaaatgg	3600
atcttgatcc	taacgatgta	acctttactt	actcacactt	cgctgtacct	caagcgaaag	3660
gaaacaatgt	cgtgattaca	agctatatga	caaacagagg	attctacgca	gacaaacaat	3720
caacggtttgc	gccgagcttc	ctgctgaaca	tcaaaggcaa	gaaaacatct	gttgtcaaaag	3780
acagcatcct	tgaacaagga	caattaacag	ttaacaaata	aaaacgcaaa	agaaaatgcc	3840
gatgggtacc	gagcgaaatg	accgaccaag	cgacgcccac	cctgccatca	cgagatttcg	3900
attccaccgc	cgccttctat	gaaagggttg	gcttcggaat	cgttttcccg	gacgccctcg	3960
cggacgtgct	catagtcac	gacgcccgtg	atthttgtag	cctggccgac	ggccagcagg	4020
taggccgaca	ggctcatgcc	ggccgcccgc	gccttttctt	caatcgctct	tcgttcgctt	4080
ggaaggcagt	acaccttgat	aggtgggctg	cccttccctg	ttggcttggt	ttcatcagcc	4140
atccgcttgc	cctcatctgt	tacgccggcg	gtagccggcc	agcctcgag	agcaggatc	4200
ccgttgagca	ccgccagggt	cgaataagg	acagtgaaga	aggaacaccc	gctcgcggt	4260
gggcctactt	cacctatcct	gcccggctga	cgccgttgga	tacaccaagg	aaagtctaca	4320
cgaacccttt	ggcaaaatcc	tgtatatcgt	gcgaaaaagg	atggatatac	cgaaaaaatc	4380
gctataatga	ccccgaagca	gggttatgca	gcggaaaagc	gctgcttccc	tgctgttttg	4440
tggaatatct	accgactgga	aacaggcaaa	tgcaggaaat	tactgaactg	aggggacagg	4500
cgagagacga	tgccaaagag	ctcctgaaaa	tctcgataac	tcaaaaaata	cgcccggtag	4560
tgatcttatt	tcattatggt	gaaagttgga	acctcttacg	tgccgatcaa	cgctctcattt	4620
tcgccaaaag	ttggcccagg	gcttcccggg	atcaacagg	acaccaggat	ttatttatcc	4680
tgcgaaagtga	tcttccgctc	caggtattta	ttcggcgcaa	agtgcgtcgg	gtgatgctgc	4740
caacttactg	atttagtgta	tgatggtgtt	tttgagggtg	tccagtggct	tctgtttcta	4800
tcagctcctg	aaaatctcga	taactcaaaa	aatacgcccg	gtagtgatct	tatttcatta	4860
tggtgaaagt	tggaacctct	tacgtgccga	tcaacgtctc	atthttcgcca	aaagttggcc	4920
cagggcttcc	cggatatcaac	agggacacca	ggatthattt	attctgcgaa	gtgatcttcc	4980
gtcacaggta	tttattcggc	gcaaagtgcg	tcgggtgatg	ctgccaactt	actgatttag	5040
tgtatgatgg	tgthtttgag	gtgctccagt	ggcttctgtt	tctatcagg	ctggatgatc	5100
ctccagcgcg	gggatctcat	gctggagttc	ttcgcccacc	ccaaaaggat	ctaggtgaag	5160
atcctttttg	ataatctcat	gacccaaaat	ccttaacgtg	agthttcggt	ccactgagcg	5220
tcagaccccc	tagaaaagat	caaaggatct	cttgagatc	ctthttttct	gcgcgtaatc	5280
tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcggtgg	tttgthttg	ggatcaagag	5340
ctaccaactc	thtttccgaa	ggtaactggc	ttcagcagag	cgagataacc	aaatactgtt	5400
cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	5460
ctcgctctgc	taatcctgtt	accagtggct	gctgccagt	gcgataagtc	gtgtcttacc	5520
gggttggtact	caagacgata	gttaccggat	aaggcgagc	ggtcgggctg	aacggggggg	5580
tcgtgcacac	agcccagctt	ggagcgaaac	acctacaccg	aactgagata	cctacagcgt	5640
gagctatgag	aaagcgccac	gcttcccga	gggagaaaag	cggacaggta	tccggtaagc	5700
ggcagggctg	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	ctgggtatct	5760
tatagtcctg	tcgggtttcg	ccacctctga	cttgagcgtc	gathtttggt	atgctcgtca	5820
ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	thtttacgggt	cctggccttt	5880
tgctggcctt	ttgctcacat	gttcttttct	gcgttatccc	ctgattctgt	ggataaccgt	5940
attaccgcct	ttgagtgagc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	6000
tcagtgagcg	aggaagcgga	agagcgccca	atacgcaaac	cgctctctcc	cgcgcttgg	6060
ccgattcatt	aatgcagctg	gcacgacagg	thttccgact	ggaaagcggg	cagtgagcgc	6120
aacgcaatta	atgtgagtta	gctcactcat	taggcacccc	aggctttaca	ctttatgctt	6180
ccggctcgta	tgthgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	6240
gacctgatt	acgccaagct	tgcctgcctg	ca			6272

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.